<?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1d3 20150301//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName JATS-journalpublishing1.dtd?>
<?SourceDTD.Version 39.96?>
<?ConverterInfo.XSLTName jats2jats3.xsl?>
<?ConverterInfo.Version 1?>
<?subarticle pone.0266929.r001?>
<?properties open_access?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">PLoS One</journal-id>
    <journal-id journal-id-type="iso-abbrev">PLoS One</journal-id>
    <journal-id journal-id-type="publisher-id">plos</journal-id>
    <journal-title-group>
      <journal-title>PLoS ONE</journal-title>
    </journal-title-group>
    <issn pub-type="epub">1932-6203</issn>
    <publisher>
      <publisher-name>Public Library of Science</publisher-name>
      <publisher-loc>San Francisco, CA USA</publisher-loc>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">9015136</article-id>
    <article-id pub-id-type="doi">10.1371/journal.pone.0266929</article-id>
    <article-id pub-id-type="publisher-id">PONE-D-21-38609</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Lab Protocol</subject>
      </subj-group>
      <subj-group subj-group-type="Discipline-v3">
        <subject>Biology and Life Sciences</subject>
        <subj-group>
          <subject>Biochemistry</subject>
          <subj-group>
            <subject>Proteins</subject>
            <subj-group>
              <subject>Intrinsically Disordered Proteins</subject>
            </subj-group>
          </subj-group>
        </subj-group>
      </subj-group>
      <subj-group subj-group-type="Discipline-v3">
        <subject>Biology and Life Sciences</subject>
        <subj-group>
          <subject>Molecular Biology</subject>
          <subj-group>
            <subject>Macromolecular Structure Analysis</subject>
            <subj-group>
              <subject>Protein Structure</subject>
            </subj-group>
          </subj-group>
        </subj-group>
      </subj-group>
      <subj-group subj-group-type="Discipline-v3">
        <subject>Biology and Life Sciences</subject>
        <subj-group>
          <subject>Biochemistry</subject>
          <subj-group>
            <subject>Proteins</subject>
            <subj-group>
              <subject>Protein Structure</subject>
            </subj-group>
          </subj-group>
        </subj-group>
      </subj-group>
      <subj-group subj-group-type="Discipline-v3">
        <subject>Biology and Life Sciences</subject>
        <subj-group>
          <subject>Molecular Biology</subject>
          <subj-group>
            <subject>Macromolecular Structure Analysis</subject>
            <subj-group>
              <subject>Protein Structure</subject>
              <subj-group>
                <subject>Protein Structure Prediction</subject>
              </subj-group>
            </subj-group>
          </subj-group>
        </subj-group>
      </subj-group>
      <subj-group subj-group-type="Discipline-v3">
        <subject>Biology and Life Sciences</subject>
        <subj-group>
          <subject>Biochemistry</subject>
          <subj-group>
            <subject>Proteins</subject>
            <subj-group>
              <subject>Protein Structure</subject>
              <subj-group>
                <subject>Protein Structure Prediction</subject>
              </subj-group>
            </subj-group>
          </subj-group>
        </subj-group>
      </subj-group>
      <subj-group subj-group-type="Discipline-v3">
        <subject>Biology and Life Sciences</subject>
        <subj-group>
          <subject>Molecular Biology</subject>
          <subj-group>
            <subject>Molecular Biology Techniques</subject>
            <subj-group>
              <subject>Molecular Biology Assays and Analysis Techniques</subject>
              <subj-group>
                <subject>Amino Acid Analysis</subject>
              </subj-group>
            </subj-group>
          </subj-group>
        </subj-group>
      </subj-group>
      <subj-group subj-group-type="Discipline-v3">
        <subject>Research and Analysis Methods</subject>
        <subj-group>
          <subject>Molecular Biology Techniques</subject>
          <subj-group>
            <subject>Molecular Biology Assays and Analysis Techniques</subject>
            <subj-group>
              <subject>Amino Acid Analysis</subject>
            </subj-group>
          </subj-group>
        </subj-group>
      </subj-group>
      <subj-group subj-group-type="Discipline-v3">
        <subject>Biology and Life Sciences</subject>
        <subj-group>
          <subject>Molecular Biology</subject>
          <subj-group>
            <subject>Molecular Biology Techniques</subject>
            <subj-group>
              <subject>Sequencing Techniques</subject>
              <subj-group>
                <subject>Protein Sequencing</subject>
              </subj-group>
            </subj-group>
          </subj-group>
        </subj-group>
      </subj-group>
      <subj-group subj-group-type="Discipline-v3">
        <subject>Research and Analysis Methods</subject>
        <subj-group>
          <subject>Molecular Biology Techniques</subject>
          <subj-group>
            <subject>Sequencing Techniques</subject>
            <subj-group>
              <subject>Protein Sequencing</subject>
            </subj-group>
          </subj-group>
        </subj-group>
      </subj-group>
      <subj-group subj-group-type="Discipline-v3">
        <subject>Physical Sciences</subject>
        <subj-group>
          <subject>Chemistry</subject>
          <subj-group>
            <subject>Chemical Reactions</subject>
            <subj-group>
              <subject>Oxidation-Reduction Reactions</subject>
            </subj-group>
          </subj-group>
        </subj-group>
      </subj-group>
      <subj-group subj-group-type="Discipline-v3">
        <subject>Physical Sciences</subject>
        <subj-group>
          <subject>Chemistry</subject>
          <subj-group>
            <subject>Electrochemistry</subject>
            <subj-group>
              <subject>Oxidation-Reduction Reactions</subject>
            </subj-group>
          </subj-group>
        </subj-group>
      </subj-group>
      <subj-group subj-group-type="Discipline-v3">
        <subject>Biology and Life Sciences</subject>
        <subj-group>
          <subject>Molecular Biology</subject>
          <subj-group>
            <subject>Macromolecular Structure Analysis</subject>
            <subj-group>
              <subject>Protein Structure</subject>
              <subj-group>
                <subject>Protein Structure Comparison</subject>
              </subj-group>
            </subj-group>
          </subj-group>
        </subj-group>
      </subj-group>
      <subj-group subj-group-type="Discipline-v3">
        <subject>Biology and Life Sciences</subject>
        <subj-group>
          <subject>Biochemistry</subject>
          <subj-group>
            <subject>Proteins</subject>
            <subj-group>
              <subject>Protein Structure</subject>
              <subj-group>
                <subject>Protein Structure Comparison</subject>
              </subj-group>
            </subj-group>
          </subj-group>
        </subj-group>
      </subj-group>
      <subj-group subj-group-type="Discipline-v3">
        <subject>Biology and Life Sciences</subject>
        <subj-group>
          <subject>Genetics</subject>
          <subj-group>
            <subject>Mutation</subject>
            <subj-group>
              <subject>Point Mutation</subject>
            </subj-group>
          </subj-group>
        </subj-group>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title><italic toggle="yes">idpr</italic>: A package for profiling and analyzing <underline>I</underline>ntrinsically <underline>D</underline>isordered <underline>P</underline>roteins in <underline>R</underline></article-title>
      <alt-title alt-title-type="running-head"><italic toggle="yes">idpr</italic>: A package for profiling and analyzing Intrinsically Disordered Proteins in R</alt-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <name>
          <surname>McFadden</surname>
          <given-names>William M.</given-names>
        </name>
        <role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
        <role content-type="http://credit.niso.org/contributor-roles/methodology/">Methodology</role>
        <role content-type="http://credit.niso.org/contributor-roles/software/">Software</role>
        <role content-type="http://credit.niso.org/contributor-roles/visualization/">Visualization</role>
        <xref rid="aff001" ref-type="aff">
          <sup>1</sup>
        </xref>
        <xref rid="currentaff001" ref-type="author-notes">
          <sup>Â¤</sup>
        </xref>
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-6886-8787</contrib-id>
        <name>
          <surname>Yanowitz</surname>
          <given-names>Judith L.</given-names>
        </name>
        <role content-type="http://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role>
        <role content-type="http://credit.niso.org/contributor-roles/project-administration/">Project administration</role>
        <role content-type="http://credit.niso.org/contributor-roles/supervision/">Supervision</role>
        <role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing â review &amp; editing</role>
        <xref rid="aff001" ref-type="aff">
          <sup>1</sup>
        </xref>
        <xref rid="aff002" ref-type="aff">
          <sup>2</sup>
        </xref>
        <xref rid="cor001" ref-type="corresp">*</xref>
      </contrib>
    </contrib-group>
    <aff id="aff001">
      <label>1</label>
      <addr-line>Magee-Womens Research Institute, Pittsburgh, PA, United States of America</addr-line>
    </aff>
    <aff id="aff002">
      <label>2</label>
      <addr-line>Department of Obstetrics, Gynecology, and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States of America</addr-line>
    </aff>
    <contrib-group>
      <contrib contrib-type="editor">
        <name>
          <surname>Permyakov</surname>
          <given-names>Eugene A.</given-names>
        </name>
        <role>Editor</role>
        <xref rid="edit1" ref-type="aff"/>
      </contrib>
    </contrib-group>
    <aff id="edit1">
      <addr-line>Russian Academy of Medical Sciences, RUSSIAN FEDERATION</addr-line>
    </aff>
    <author-notes>
      <fn fn-type="COI-statement" id="coi001">
        <p><bold>Competing Interests: </bold>he authors have declared that no competing interests exist.</p>
      </fn>
      <fn fn-type="current-aff" id="currentaff001">
        <label>Â¤</label>
        <p>Current address: Department of Pediatrics, Laboratory of Biochemical Pharmacology, Emory University School of Medicine, Atlanta, GA, United States of America</p>
      </fn>
      <corresp id="cor001">* E-mail: <email>yanowitzjl@mwri.magee.edu</email></corresp>
    </author-notes>
    <pub-date pub-type="epub">
      <day>18</day>
      <month>4</month>
      <year>2022</year>
    </pub-date>
    <pub-date pub-type="collection">
      <year>2022</year>
    </pub-date>
    <volume>17</volume>
    <issue>4</issue>
    <elocation-id>e0266929</elocation-id>
    <history>
      <date date-type="received">
        <day>6</day>
        <month>12</month>
        <year>2021</year>
      </date>
      <date date-type="accepted">
        <day>29</day>
        <month>3</month>
        <year>2022</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>Â© 2022 McFadden, Yanowitz</copyright-statement>
      <copyright-year>2022</copyright-year>
      <copyright-holder>McFadden, Yanowitz</copyright-holder>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
        <license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
      </license>
    </permissions>
    <self-uri content-type="pdf" xlink:href="pone.0266929.pdf"/>
    <related-object document-id="10.17504/protocols.io.kqdg3p241l25/v1" document-id-type="doi" specific-use="protocol" id="rel-obj001"/>
    <abstract>
      <p>Intrinsically disordered proteins (IDPs) and intrinsically disordered regions (IDRs) are proteins or protein-domains that do not have a single native structure, rather, they are a class of flexible peptides that can rapidly adopt multiple conformations. IDPs are quite abundant, and their dynamic characteristics provide unique advantages for various biological processes. The field of âunstructured biologyâ has emerged, in part, because of numerous computational studies that had identified the unique characteristics of IDPs and IDRs. The package â<italic toggle="yes">idpr</italic>â, short for <bold>I</bold>ntrinsically <bold>D</bold>isordered <bold>P</bold>roteins in <bold>R</bold>, implements several R functions that match the established characteristics of IDPs to protein sequences of interest. This includes calculations of residue composition, charge-hydropathy relationships, and predictions of intrinsic disorder. Additionally, <italic toggle="yes">idpr</italic> integrates several amino acid substitution matrices and calculators to supplement IDP-based workflows. Overall, <italic toggle="yes">idpr</italic> aims to integrate tools for the computational analysis of IDPs within R, facilitating the analysis of these important, yet under-characterized, proteins. The <italic toggle="yes">idpr</italic> package can be downloaded from Bioconductor (<ext-link xlink:href="https://bioconductor.org/packages/idpr/" ext-link-type="uri">https://bioconductor.org/packages/idpr/</ext-link>).</p>
    </abstract>
    <funding-group>
      <award-group id="award001">
        <funding-source>
          <institution>National Institute of General Medical Sciences</institution>
        </funding-source>
        <award-id>R01GM127569</award-id>
        <principal-award-recipient>
          <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-6886-8787</contrib-id>
          <name>
            <surname>Yanowitz</surname>
            <given-names>Judith L.</given-names>
          </name>
        </principal-award-recipient>
      </award-group>
      <funding-statement>This work was funded by National Institutes of Health, grant #R01GM127569 to Judith Yanowitz. <ext-link xlink:href="https://public.era.nih.gov/commonsplus/" ext-link-type="uri">https://public.era.nih.gov/commonsplus/</ext-link>. The funders had and will not have a role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement>
    </funding-group>
    <counts>
      <fig-count count="3"/>
      <table-count count="0"/>
      <page-count count="12"/>
    </counts>
    <custom-meta-group>
      <custom-meta id="data-availability">
        <meta-name>Data Availability</meta-name>
        <meta-value>idpr is available for download at: <ext-link xlink:href="https://doi.org/10.18129/B9.bioc.idpr" ext-link-type="uri">https://doi.org/10.18129/B9.bioc.idpr</ext-link>.</meta-value>
      </custom-meta>
    </custom-meta-group>
  </article-meta>
  <notes>
    <title>Data Availability</title>
    <p>idpr is available for download at: <ext-link xlink:href="https://doi.org/10.18129/B9.bioc.idpr" ext-link-type="uri">https://doi.org/10.18129/B9.bioc.idpr</ext-link>.</p>
  </notes>
</front>
<body>
  <sec sec-type="intro" id="sec001">
    <title>Introduction</title>
    <p>Intrinsically disordered proteins (IDPs) are proteins that lack a single, rigid structure under native conditions [<xref rid="pone.0266929.ref001" ref-type="bibr">1</xref>â<xref rid="pone.0266929.ref004" ref-type="bibr">4</xref>], challenging the long-held paradigm that structure leads to function. In addition to typical cellular processes, IDPs have been implicated in human diseases such as neurodegenerative disorders and various cancers [<xref rid="pone.0266929.ref005" ref-type="bibr">5</xref>â<xref rid="pone.0266929.ref007" ref-type="bibr">7</xref>]. IDPs contain one or more intrinsically disordered region (IDR), which are regions of proteins composed of thirty or more disordered residues. Bioinformatic studies have shown that one-third to one-half of eukaryotic proteomes are predicted IDPs [<xref rid="pone.0266929.ref008" ref-type="bibr">8</xref>â<xref rid="pone.0266929.ref011" ref-type="bibr">11</xref>]. Further, viral proteomes appear to be enriched in IDPs, exemplified with the most disordered proteome observed belonging to the <italic toggle="yes">Avian carcinoma virus</italic> with an average disorder composition of over 77% [<xref rid="pone.0266929.ref009" ref-type="bibr">9</xref>].</p>
    <p>Due to their apparent abundance and relevance, research interest in IDPs has been increasing [<xref rid="pone.0266929.ref012" ref-type="bibr">12</xref>]. In this regard, there are many computational tools that predict the intrinsic disorder within a protein sequence [<xref rid="pone.0266929.ref013" ref-type="bibr">13</xref>â<xref rid="pone.0266929.ref015" ref-type="bibr">15</xref>]. These tools utilize known differences between disordered and ordered proteins, such as the distinct compositional profile, evolutionary rate, and biochemical properties of IDPs and IDRs compared to proteins or protein-regions with compact, ordered structure [<xref rid="pone.0266929.ref016" ref-type="bibr">16</xref>â<xref rid="pone.0266929.ref019" ref-type="bibr">19</xref>]. Since IDPs have decreased levels of secondary and tertiary structures [<xref rid="pone.0266929.ref001" ref-type="bibr">1</xref>], the primary structure serves as the principal source of computational information for IDPs. Thus, most IDP prediction tools rely on the proteinâs sequence of amino acids, commonly represented as a character string of individual letters [<xref rid="pone.0266929.ref013" ref-type="bibr">13</xref>â<xref rid="pone.0266929.ref015" ref-type="bibr">15</xref>]. While several R packages analyze protein characteristics based on the amino acid sequence alone, to our knowledge, there is not been a package that is focused on the unique features of IDPs and IDRs.</p>
    <p>The R package that we created borrows its acronym from âIDPRâ or Intrinsically Disordered Protein Regions; <italic toggle="yes">idpr</italic> stands for âIntrinsically Disordered Proteins in Râ. The goal of this R package is to integrate tools for IDP analysis, including amino acid composition, charge, and hydropathy, using the R platform. Additional IDP analysis is facilitated by several amino acid substitution matrices that are IDP-specific [<xref rid="pone.0266929.ref020" ref-type="bibr">20</xref>â<xref rid="pone.0266929.ref022" ref-type="bibr">22</xref>] as well as linking to the suite of disorder predictions by IUPred2A [<xref rid="pone.0266929.ref023" ref-type="bibr">23</xref>, <xref rid="pone.0266929.ref024" ref-type="bibr">24</xref>] retrieved by connection to their REST API. The <italic toggle="yes">idpr</italic> package can be found at <ext-link xlink:href="https://bioconductor.org/packages/idpr/" ext-link-type="uri">https://bioconductor.org/packages/idpr/</ext-link>.</p>
    <p><italic toggle="yes">idpr</italic> aims to balance a workflow that automatically generates key visualizations for users of any skill level with a workflow that allows dynamic input and custom output for more-experienced users. The <italic toggle="yes">ggplot2</italic> package [<xref rid="pone.0266929.ref025" ref-type="bibr">25</xref>] is used to generate the visualizations, allowing users to access ggplot theme options and aesthetics for further customization. Additionally, <italic toggle="yes">idpr</italic> graphic functions give users the option to return calculations as values for downstream analysis. Overall, <italic toggle="yes">idpr</italic> aims to integrate multiple tools for the computational analysis of intrinsically disordered proteins within R.</p>
  </sec>
  <sec sec-type="materials|methods" id="sec002">
    <title>Methods</title>
    <sec id="sec003">
      <title>A. Implementation</title>
      <p><italic toggle="yes">idpr</italic> is implemented as an open-source R [<xref rid="pone.0266929.ref026" ref-type="bibr">26</xref>] / Bioconductor [<xref rid="pone.0266929.ref027" ref-type="bibr">27</xref>] package under an LGPL-3 license. For integration with various packages, <italic toggle="yes">idpr</italic> functions accept protein sequences as character strings, vectors of individual amino acids, and XString objects from the Biostrings package [<xref rid="pone.0266929.ref028" ref-type="bibr">28</xref>]. Alternatively, functions can analyze sequences directly from.fasta files. Substitution matrices within this package can integrate with other R packages used for sequence analysis and multiple sequence alignments. Package dependencies include R version 4.1.3, <italic toggle="yes">Biostrings</italic> [<xref rid="pone.0266929.ref028" ref-type="bibr">28</xref>], <italic toggle="yes">jsonlite</italic> [<xref rid="pone.0266929.ref029" ref-type="bibr">29</xref>], and several tidverse packages [<xref rid="pone.0266929.ref030" ref-type="bibr">30</xref>] including <italic toggle="yes">ggplot2</italic> [<xref rid="pone.0266929.ref025" ref-type="bibr">25</xref>].</p>
      <p><italic toggle="yes">idpr</italic> is a well-documented package with detailed user manuals and function descriptions, generated with <italic toggle="yes">roxygen2</italic> [<xref rid="pone.0266929.ref031" ref-type="bibr">31</xref>]. This package also includes six vignette documents (long-form documentation) that discusses the theories of IDPs with the functionality of the package. Versions of <italic toggle="yes">idpr</italic> can be installed through the <italic toggle="yes">BiocManager</italic> package manager [<xref rid="pone.0266929.ref032" ref-type="bibr">32</xref>] from Bioconductor Release â¥3.13 (<ext-link xlink:href="http://bioconductor.org" ext-link-type="uri">bioconductor.org</ext-link>) with the following line of R code: BiocManager::install("idpr"). <italic toggle="yes">idpr</italic> version 1.5.11 was used for this publication and the workflow can be found in the supplementary materials or at <ext-link xlink:href="http://dx.doi.org/10.17504/protocols.io.kqdg3p241l25/v1" ext-link-type="uri">dx.doi.org/10.17504/protocols.io.kqdg3p241l25/v1</ext-link>.</p>
    </sec>
    <sec id="sec004">
      <title>B. âidprofileâ</title>
      <p>To quickly generate the <italic toggle="yes">idpr</italic> profile for a protein of interest, a UniProt ID and the amino acid sequence are used to create multiple plots with a single command. idprofile() serves as a wrapping function for key graphing tools within <italic toggle="yes">idpr</italic>. These plots include: Charge-Hydropathy Plot, Local Charge Plot, Local Scaled Hydropathy Plot, Structural Tendency Plot, Compositional Profile Plot, and IUPred Plot, and FoldIndex Plot (Discussed Below). If a UniPot ID is not included, the IUPred plot is skipped (<xref rid="pone.0266929.g001" ref-type="fig">Fig 1</xref>). Please refer to the supplementary workflow and package documentation for details on using idprofile and other <italic toggle="yes">idpr</italic> functions.</p>
      <fig position="float" id="pone.0266929.g001">
        <object-id pub-id-type="doi">10.1371/journal.pone.0266929.g001</object-id>
        <label>Fig 1</label>
        <caption>
          <title>The idprofile of Î±-Synuclein, generated by <italic toggle="yes">idpr</italic>, returns IDP characteristics.</title>
          <p>(A) Charge-hydropathy plot of Î±-Synuclein (Î±Syn) predicts a collapsed protein. Method are described in [<xref rid="pone.0266929.ref016" ref-type="bibr">16</xref>]. Mean Scaled Hydropathy calculated with the Kyte and Doolittle measurement of hydropathy [<xref rid="pone.0266929.ref033" ref-type="bibr">33</xref>], scaled to Arg = 0.0 and Ile = 1.0. Mean Net Charge calculated with IPC_protein pKa values [<xref rid="pone.0266929.ref034" ref-type="bibr">34</xref>]. Cutoff equation is &lt;Charge&gt; = Â±2.785&lt;Hydropathy&gt;Â±1.151 as described previously [<xref rid="pone.0266929.ref018" ref-type="bibr">18</xref>]. Proteins are considered insoluble when &lt;Hydropathy&gt; â¥ 0.7. (B) Structural tendency plot shows Î±Syn is enriched in disorder-promoting residues. Disorder-promoting residues (P, E, S, Q, K, A, and G) in green; order-promoting residues (M, N, V, H, L, F, Y, I, W, and C) in purple; disorderâneutral residues (D, T, and R) in pink [<xref rid="pone.0266929.ref035" ref-type="bibr">35</xref>]. (C) Local Charge Plot shows an acidic C-terminus. The local charge is the average of a 9 amino acid wide sliding window, calculated with the IPC_protein pKa values [<xref rid="pone.0266929.ref034" ref-type="bibr">34</xref>]. (D) Local Hydropathy Plot shows a C-terminus deficient in hydrophobic residues. The local hydropathy is the average of a 9 amino acid wide sliding window, calculated with the scaled Kyte and Doolittle measurement of hydropathy [<xref rid="pone.0266929.ref033" ref-type="bibr">33</xref>]. (E) IUPred2 predicts a C-terminal IDR in Î±Syn [<xref rid="pone.0266929.ref023" ref-type="bibr">23</xref>, <xref rid="pone.0266929.ref024" ref-type="bibr">24</xref>]. Residues with a score 0.0â0.5 are predicted to be ordered, regions 0.5â1.0 are predicted to be disordered. (F) FoldIndex predicts a C-terminal IDR in Î±Syn [<xref rid="pone.0266929.ref036" ref-type="bibr">36</xref>]. Residues with a score 0.0 â+1.0 are predicted to be ordered, regions -1.0â0.0 are predicted to be disordered.</p>
        </caption>
        <graphic xlink:href="pone.0266929.g001" position="float"/>
      </fig>
    </sec>
    <sec id="sec005">
      <title>C. Charge and hydropathy</title>
      <p>It has been previously shown that both extreme net charge and deficiency in hydropathy are characteristics of intrinsic disorder proteins [<xref rid="pone.0266929.ref016" ref-type="bibr">16</xref>]. Extended IDPs will occupy a unique area on the plots of both average net charge and mean scaled hydropathy, [<xref rid="pone.0266929.ref016" ref-type="bibr">16</xref>]. meaning that the Charge-Hydropathy Plot can distinguish compact from extended proteins under native conditions (<xref rid="pone.0266929.g001" ref-type="fig">Fig 1A</xref>). One cannot, however, make a general rule about where IDPs on the spectrum from collapsed protein or an extended protein because IDPs can have the characteristics of either [<xref rid="pone.0266929.ref016" ref-type="bibr">16</xref>, <xref rid="pone.0266929.ref037" ref-type="bibr">37</xref>].</p>
      <p>Protein charges are calculated using the Henderson-Hasselbalch equation [<xref rid="pone.0266929.ref038" ref-type="bibr">38</xref>] with the IPC_protein pKa values [<xref rid="pone.0266929.ref034" ref-type="bibr">34</xref>] by default, although 15 additional pKa data sets are loaded into <italic toggle="yes">idpr</italic> for user preference. The Kyte and Doolittle measurement of hydropathy [<xref rid="pone.0266929.ref033" ref-type="bibr">33</xref>] are used, scaled with Arg having a hydropathy of 0.0 and Ile having a hydropathy of 1.0. Local charges and local hydropathy are calculated using a sliding window to identify regions of interesting chemistry (<xref rid="pone.0266929.g001" ref-type="fig">Fig 1C and 1D</xref>). The sliding window is 9 residues by default but can be changed to any odd number. The resulting figure is similar to one that can be obtained by the ProtScale tool from ExPASy [<xref rid="pone.0266929.ref039" ref-type="bibr">39</xref>].</p>
    </sec>
    <sec id="sec006">
      <title>D. Structural tendency</title>
      <p>IDPs as a class tends to have a different composition of amino acids, and therefore distinct overall chemistry, from that of ordered proteins [<xref rid="pone.0266929.ref040" ref-type="bibr">40</xref>]. The chemistry of the specific residues influences its tendency to favor an extended or a compact structure. Residues enriched in the amino acid sequences of IDPs are typically charged, flexible, hydrophilic, or small; whereas order-promoting residues, found in structured proteins, tend to be hydrophobic, aromatic, aliphatic, or disulfide bond. There are also disorder-neutral residues [<xref rid="pone.0266929.ref018" ref-type="bibr">18</xref>, <xref rid="pone.0266929.ref035" ref-type="bibr">35</xref>]. The default values, described previously [<xref rid="pone.0266929.ref035" ref-type="bibr">35</xref>], are disorder-promoting residues: P, E, S, Q, K, A, and G; order-promoting residues: M, N, V, H, L, F, Y, I, W, and C; and disorderâneutral residues: D, T, and R. These are represented by the structural tendency plot (<xref rid="pone.0266929.g001" ref-type="fig">Fig 1B</xref>). Other definitions of order- and disorder-promoting have been published [<xref rid="pone.0266929.ref011" ref-type="bibr">11</xref>], so users can opt to manually specify residue definitions.</p>
    </sec>
    <sec id="sec007">
      <title>E. Disorder predictions</title>
      <p>FoldIndex utilizes the described relationship of charge and hydropathy to identify unstructured regions of amino acid sequences [<xref rid="pone.0266929.ref016" ref-type="bibr">16</xref>, <xref rid="pone.0266929.ref036" ref-type="bibr">36</xref>]. This method is implemented as part of many other prediction programs since it was described in 2005. Using a sliding window of size 51, a negative score (&lt;0) indicates a region is predicted disordered; windows with a positive score (&gt;0) are predicted as ordered [<xref rid="pone.0266929.ref036" ref-type="bibr">36</xref>]. Calculations are made with charge and hydropathy functions within <italic toggle="yes">idpr</italic> and uses IPC_protein pKa values [<xref rid="pone.0266929.ref034" ref-type="bibr">34</xref>] at pH 7.0 and the scaled Kyte and Doolittle measurement of hydropathy [<xref rid="pone.0266929.ref033" ref-type="bibr">33</xref>].</p>
      <p>The IUPred2 algorithm calculates a score of intrinsic disorder based on a model of the estimated energy potential for each residue interactions [<xref rid="pone.0266929.ref023" ref-type="bibr">23</xref>]. The structure in protein comes from a network of intramolecular interactions between amino acids. In IDPs, the (lack of) structure comes from the increase interactions of the amino acids with the surrounding environment. This reduced number of interactions leads to the IDP lacking secondary and tertiary structure [<xref rid="pone.0266929.ref041" ref-type="bibr">41</xref>]. IUPred2 predictions are made on a scale of 0.0â1.0, with 0.5 being the dividing line between order and disorder. &gt;0.5 predicting a disordered region; &lt;0.5 predicting an ordered region [<xref rid="pone.0266929.ref023" ref-type="bibr">23</xref>, <xref rid="pone.0266929.ref024" ref-type="bibr">24</xref>, <xref rid="pone.0266929.ref041" ref-type="bibr">41</xref>] (<xref rid="pone.0266929.g001" ref-type="fig">Fig 1E</xref>). An additional prediction of intermolecular protein-protein interactions is performed with the ANCHOR2 program (<xref rid="pone.0266929.g002" ref-type="fig">Fig 2A</xref>), and another predictor of redox-sensitive disorder is performed with IUPred2A Redox (<xref rid="pone.0266929.g002" ref-type="fig">Fig 2B</xref>) [<xref rid="pone.0266929.ref023" ref-type="bibr">23</xref>, <xref rid="pone.0266929.ref024" ref-type="bibr">24</xref>, <xref rid="pone.0266929.ref041" ref-type="bibr">41</xref>]. A Uniprot ID is required to access the IUPred2A REST API, as well as an internet connection. Visit the IUPred2A website (<ext-link xlink:href="https://iupred2a.elte.hu/" ext-link-type="uri">https://iupred2a.elte.hu/</ext-link>) for terms of use, references, and additional information.</p>
      <fig position="float" id="pone.0266929.g002">
        <object-id pub-id-type="doi">10.1371/journal.pone.0266929.g002</object-id>
        <label>Fig 2</label>
        <caption>
          <title>Disorder predictions for p53 domains recapitulate environmental sensitivities.</title>
          <p>(A) IUPred2A predicts multiple IDRs that promote protein-protein interactions in p53 [<xref rid="pone.0266929.ref023" ref-type="bibr">23</xref>, <xref rid="pone.0266929.ref024" ref-type="bibr">24</xref>]. Residues with an IUPred2 score (green and purple line) of 0.0â0.5 are predicted to be ordered and residues 0.5â1.0 are predicted to be disordered. Residues with an ANCHOR2 score (red line) greater than 0.5 are predicted to be IDRs and protein-binding domains. (B) IUPred2A Redox predicts several oxidation-sensitive regions in p53 [<xref rid="pone.0266929.ref023" ref-type="bibr">23</xref>, <xref rid="pone.0266929.ref024" ref-type="bibr">24</xref>]. Redox-plus (reducing environment) predictions are shown in blue, Redox-minus (oxidizing environment) predictions are shown in purple. Regions predicted as âRedox Sensitiveâ are highlighted in light green. Residues with an IUPred score of 0.0â0.5 are predicted to be ordered and residues 0.5â1.0 are predicted to be disordered. (C) Sequence map of structural tendency for each residue highlights the composition of p53 domains. N-terminal Domain (NTD) annotated by the black bar, DNA-Binding Domain (DBD) annotated by the red bar, C-terminal Domain (CTD) annotated by the grey bar. Conserved Cys residues (C124, C135, C141, C176, C182, C229, C238, C242, C275, C277] annotated [<xref rid="pone.0266929.ref042" ref-type="bibr">42</xref>]. Disorder-promoting residues (P, E, S, Q, K, A, and G) highlighted in green; order-promoting residues (M, N, V, H, L, F, Y, I, W, and C) in purple; disorderâneutral residues (D, T, and R) in pink [<xref rid="pone.0266929.ref035" ref-type="bibr">35</xref>].</p>
        </caption>
        <graphic xlink:href="pone.0266929.g002" position="float"/>
      </fig>
    </sec>
    <sec id="sec008">
      <title>F. Visualizing discrete values</title>
      <p>As mentioned above, specific amino acid residues are preferentially enriched in unstructured or ordered regions [<xref rid="pone.0266929.ref035" ref-type="bibr">35</xref>]. To visualize the location of assigned residue characteristics in the context of the amino acid sequence, <italic toggle="yes">idpr</italic> contains a way to visualize discrete values with a âsequenceMapâ (<xref rid="pone.0266929.g002" ref-type="fig">Fig 2C</xref>, S1B Fig in <xref rid="pone.0266929.s001" ref-type="supplementary-material">S1 File</xref>). This is not part of the idprofile function but is included within the package for additional investigation. The values visualized can be results from <italic toggle="yes">idpr</italic> or from any other source. This function can also visualize continuous values.</p>
    </sec>
    <sec id="sec009">
      <title>G. Substitution matrices for analyzing IDPs</title>
      <p>Because there is less restraint to maintain a specific 3D structure IDPs and IDRs tend to evolve faster than ordered proteins [<xref rid="pone.0266929.ref017" ref-type="bibr">17</xref>, <xref rid="pone.0266929.ref043" ref-type="bibr">43</xref>]. Therefore, IDPs tend to accept increased point mutations at disparate rates when compared to ordered proteins [<xref rid="pone.0266929.ref021" ref-type="bibr">21</xref>].</p>
      <p>Currently, PAM and BLOSUM are the most amino acid substitution matrices [<xref rid="pone.0266929.ref044" ref-type="bibr">44</xref>, <xref rid="pone.0266929.ref045" ref-type="bibr">45</xref>], which are integrated into many web-based tools including NCBI-BLAST+ and EMBOSS [<xref rid="pone.0266929.ref046" ref-type="bibr">46</xref>, <xref rid="pone.0266929.ref047" ref-type="bibr">47</xref>]. However, customization of the matrices is often desired but is not possible with these online programs. That said, BLOSUM and PAM matrices can both be used with alignment programs in R when loaded via the Biostrings Package [<xref rid="pone.0266929.ref028" ref-type="bibr">28</xref>]. However, for the analysis of IDPs, PAM and BLOSUM matrices are not ideals since they are derived from ordered proteins or favor residue substitutions common among structured proteins [<xref rid="pone.0266929.ref020" ref-type="bibr">20</xref>â<xref rid="pone.0266929.ref022" ref-type="bibr">22</xref>]. To circumvent this pitfall in <italic toggle="yes">idpr</italic>, EDSSMat [<xref rid="pone.0266929.ref020" ref-type="bibr">20</xref>], Disorder [<xref rid="pone.0266929.ref021" ref-type="bibr">21</xref>], and DUNMat [<xref rid="pone.0266929.ref022" ref-type="bibr">22</xref>] which provide IDP-derived substitution matrices have been incorporated for use in alignments.</p>
    </sec>
  </sec>
  <sec sec-type="conclusions" id="sec010">
    <title>Results and discussion</title>
    <sec id="sec011">
      <title>A. Example 1 - Î±-Synuclein</title>
      <p>To highlight the use of the <italic toggle="yes">idpr</italic> package, Î±-Synuclein (Î±Syn; UniProt ID: P37840], is used in an example analysis. Î±Syn is an IDP, experimentally validated using various methods [<xref rid="pone.0266929.ref048" ref-type="bibr">48</xref>â<xref rid="pone.0266929.ref052" ref-type="bibr">52</xref>]. This protein has been extensively studied and is heavily implicated in Parkinsonâs Disease pathology [<xref rid="pone.0266929.ref053" ref-type="bibr">53</xref>, <xref rid="pone.0266929.ref054" ref-type="bibr">54</xref>]. The idprofile of Î±Syn returns IDP characteristics (<xref rid="pone.0266929.g001" ref-type="fig">Fig 1</xref>]. The Charge-Hydropathy plot shows that Î±Syn appears to be a collapsed protein, rather than an extended IDP (<xref rid="pone.0266929.g001" ref-type="fig">Fig 1A</xref>). This is in line with previous reported data showing regions of Î±Syn are shielded from the cytoplasm under native conditions [<xref rid="pone.0266929.ref049" ref-type="bibr">49</xref>]. The structural tendency plot shows that Î±Syn is enriched in disorder-promoting residues, mostly represented by Glu, Lys, Ala, and Gly (<xref rid="pone.0266929.g001" ref-type="fig">Fig 1B</xref>). Interestingly, Î±Syn lacks Cys and Trp, both of which are the most order-promoting residues [<xref rid="pone.0266929.ref035" ref-type="bibr">35</xref>], in addition to lacking Arg, a positively charged and order-neutral residue. The local charges of the protein are mostly neutral, apart from a negatively charged C-terminal region (<xref rid="pone.0266929.g001" ref-type="fig">Fig 1C</xref>). In conjunction with the local charge, the C-terminal region is deficient in hydrophobic residues, as shown by the local scaled hydropathy (<xref rid="pone.0266929.g001" ref-type="fig">Fig 1D</xref>). In fact, it has been reported that residues 104â140 of Î±Syn are more extended than the N-terminal portion of the protein [<xref rid="pone.0266929.ref051" ref-type="bibr">51</xref>]. The Charge-Hydropathy plot of Î±Syn residues 104â140 returns an extended IDR, while residues 1â103 returns a collapsed protein with a more neutral charge (S1A Fig in <xref rid="pone.0266929.s001" ref-type="supplementary-material">S1 File</xref>). This is in line with the IUPred2 and FoldIndex predictions of intrinsic disorder for Î±Syn, which shows the C-terminal region predicted as disordered (<xref rid="pone.0266929.g001" ref-type="fig">Fig 1E and 1F</xref>, S1B Fig in <xref rid="pone.0266929.s001" ref-type="supplementary-material">S1 File</xref>). There are known point mutations in Î±Syn that are associated with familial Parkinsonâs Disease: A30P, E46K, H50Q, G51D, and A53T [<xref rid="pone.0266929.ref055" ref-type="bibr">55</xref>â<xref rid="pone.0266929.ref057" ref-type="bibr">57</xref>]. While these mutations are located in the more compact region of the protein, most mutations occur in disorder-promoting residues, with the exception of H50Q (S1B Fig in <xref rid="pone.0266929.s001" ref-type="supplementary-material">S1 File</xref>). Overall, the idprofile is useful for identifying biochemical features related to IDRs within a protein of interest.</p>
    </sec>
    <sec id="sec012">
      <title>B. Example 2âp53</title>
      <p>Another well characterized IDP is the cellular tumor antigen p53 (UniProt ID: P04637]. p53 has been studied extensively since it is mutated in over 50% of human cancers [<xref rid="pone.0266929.ref058" ref-type="bibr">58</xref>, <xref rid="pone.0266929.ref059" ref-type="bibr">59</xref>]. It is an experimentally validated IDP [<xref rid="pone.0266929.ref060" ref-type="bibr">60</xref>â<xref rid="pone.0266929.ref062" ref-type="bibr">62</xref>] that acts as a protein hub, interacting with many different partners [<xref rid="pone.0266929.ref003" ref-type="bibr">3</xref>, <xref rid="pone.0266929.ref063" ref-type="bibr">63</xref>]. The idprofile of p53 shows characteristics of a protein with several IDRs (S2 Fig in <xref rid="pone.0266929.s001" ref-type="supplementary-material">S1 File</xref>). The C-terminal domain (CTD) of p53 has been highly studied due to its ability to reversibly form various secondary structures depending on the specific binding partner studied [<xref rid="pone.0266929.ref003" ref-type="bibr">3</xref>, <xref rid="pone.0266929.ref060" ref-type="bibr">60</xref>, <xref rid="pone.0266929.ref063" ref-type="bibr">63</xref>]. For example, residues 377â388 gain an Î±-helical structure when interacting with S100 calcium-binding protein B, while in the same region, residues 379â387, form a Î²-strand when interacting with Sirtuin [<xref rid="pone.0266929.ref003" ref-type="bibr">3</xref>, <xref rid="pone.0266929.ref060" ref-type="bibr">60</xref>, <xref rid="pone.0266929.ref063" ref-type="bibr">63</xref>]. To predict such regions, ANCHOR2 scores, produced by IUPred2A, predict domains that are disordered and are protein-binding regions which may undergo a gain-of-structure when bound [<xref rid="pone.0266929.ref023" ref-type="bibr">23</xref>, <xref rid="pone.0266929.ref024" ref-type="bibr">24</xref>]. For p53, ANCHOR2 predicts binding in multiple IDRs, including the CTD and recapitulates the known disorder-to-order transition of this domain mentioned above (<xref rid="pone.0266929.g002" ref-type="fig">Fig 2A</xref>).</p>
      <p>There are several evolutionarily conserved cysteines within p53, most of which are within the central DNA-binding domain (DBD) [<xref rid="pone.0266929.ref042" ref-type="bibr">42</xref>, <xref rid="pone.0266929.ref064" ref-type="bibr">64</xref>]. Further, p53 has reported roles in redox regulation [<xref rid="pone.0266929.ref042" ref-type="bibr">42</xref>, <xref rid="pone.0266929.ref065" ref-type="bibr">65</xref>, <xref rid="pone.0266929.ref066" ref-type="bibr">66</xref>]. To this point, IUPred2 contains a context-dependent predictor of disorder distinguishing between reducing (plus) or oxidizing (minus) environments that can be used to predict redox-sensitive IDRs that may experience induced folding [<xref rid="pone.0266929.ref023" ref-type="bibr">23</xref>, <xref rid="pone.0266929.ref024" ref-type="bibr">24</xref>]. IUPred2 Redox predicts that p53 has multiple regions of redox sensitivity in the DBD (<xref rid="pone.0266929.g002" ref-type="fig">Fig 2B</xref>). This is in line with the known impact of redox conditions on the DBD that influences the structureâand the subsequent functionâof p53, consistent with published literature [<xref rid="pone.0266929.ref064" ref-type="bibr">64</xref>, <xref rid="pone.0266929.ref065" ref-type="bibr">65</xref>, <xref rid="pone.0266929.ref067" ref-type="bibr">67</xref>, <xref rid="pone.0266929.ref068" ref-type="bibr">68</xref>]. The structural tendency of each residue in p53 is highlighted in a sequence map with domains [<xref rid="pone.0266929.ref060" ref-type="bibr">60</xref>] and conserved Cys residues [<xref rid="pone.0266929.ref042" ref-type="bibr">42</xref>] annotated (<xref rid="pone.0266929.g002" ref-type="fig">Fig 2C</xref>). This p53 analysis exemplifies the use of functions within <italic toggle="yes">idpr</italic> that are not automatically generated using the idprofile wrapping function.</p>
    </sec>
    <sec id="sec013">
      <title>C. Example 3 âmouse GCNA</title>
      <p>The germ cell nuclear acidic protein (GCNA) is required for male fertility and has roles in repairing DNA-protein crosslinks [<xref rid="pone.0266929.ref069" ref-type="bibr">69</xref>â<xref rid="pone.0266929.ref071" ref-type="bibr">71</xref>]. GCNA has orthologs from single-celled protists to mammals. In most species, the N-terminal half of GCNA is disordered and the C-terminal half contains an Sprt-Like metalloprotease domain, zinc finger, and HMG box. While there appears to be occasional losses of either the protease, HMG box, or zinc finger, all GCNA orthologs contain the IDR [<xref rid="pone.0266929.ref070" ref-type="bibr">70</xref>]. The IDR of GCNA is enriched in acidic residues, which contributes to the disordered nature. Interestingly, the mouse GCNA lacks all of the structured domains and was previously predicted to be entirely disordered by IUPRED [<xref rid="pone.0266929.ref070" ref-type="bibr">70</xref>, <xref rid="pone.0266929.ref072" ref-type="bibr">72</xref>].</p>
      <p>The idprofile of mouse GCNA (UniProt ID: A0A1D9BZF0) displays that of an unstructured protein (<xref rid="pone.0266929.g003" ref-type="fig">Fig 3A</xref>). There is a long stretch of acidic residues, with glutamic acid (E) being the most abundant residue in the amino acid sequence (<xref rid="pone.0266929.g003" ref-type="fig">Fig 3B and 3C</xref>). Further, there is a significant enrichment of disorder promoting residues in mouse GCNA (<xref rid="pone.0266929.g003" ref-type="fig">Fig 3B</xref>), aligning with the previously reported amino acid composition of GCNA being similar to that of Disprot, a database of intrinsically disordered proteins [<xref rid="pone.0266929.ref070" ref-type="bibr">70</xref>, <xref rid="pone.0266929.ref073" ref-type="bibr">73</xref>]. There are very few hydrophobic residues, and the protein has an average scaled hydropathy of 0.348 (<xref rid="pone.0266929.g003" ref-type="fig">Fig 3D</xref>). Both the extreme acidity of GCNA and the enrichment of disorder-promoting soluble residues contribute to the entire peptide being predicted as disordered from N- to C-terminus (<xref rid="pone.0266929.g003" ref-type="fig">Fig 3E and 3F</xref>). This replicates previously reported predictions of mouse GCNA being disordered [<xref rid="pone.0266929.ref070" ref-type="bibr">70</xref>].</p>
      <fig position="float" id="pone.0266929.g003">
        <object-id pub-id-type="doi">10.1371/journal.pone.0266929.g003</object-id>
        <label>Fig 3</label>
        <caption>
          <title>The idprofile of mouse GCNA shows prediction of an entirely disordered IDP.</title>
          <p>(A) Charge-hydropathy plot of GCNA predicts a disordered protein. Method are described in [<xref rid="pone.0266929.ref016" ref-type="bibr">16</xref>]. Mean Scaled Hydropathy calculated with the Kyte and Doolittle measurement of hydropathy [<xref rid="pone.0266929.ref033" ref-type="bibr">33</xref>], scaled to Arg = 0.0 and Ile = 1.0. Mean Net Charge calculated with IPC_protein pKa values [<xref rid="pone.0266929.ref034" ref-type="bibr">34</xref>]. Cutoff equation is &lt;Charge&gt; = Â±2.785&lt;Hydropathy&gt;Â±1.151 as described previously [<xref rid="pone.0266929.ref018" ref-type="bibr">18</xref>]. Proteins are considered insoluble when &lt;Hydropathy&gt; â¥ 0.7. (B) Structural tendency plot shows GCNA is enriched in disorder-promoting residues. Disorder-promoting residues (P, E, S, Q, K, A, and G) in green; order-promoting residues (M, N, V, H, L, F, Y, I, W, and C) in purple; disorderâneutral residues (D, T, and R) in pink [<xref rid="pone.0266929.ref035" ref-type="bibr">35</xref>]. (C) Local Charge Plot shows an acidic C-terminus. The local charge is the average of a 7 amino acid wide sliding window, calculated with the IPC_protein pKa values [<xref rid="pone.0266929.ref034" ref-type="bibr">34</xref>]. (D) Local Hydropathy Plot shows a C-terminus deficient in hydrophobic residues. The local hydropathy is the average of a 9 amino acid wide sliding window, calculated with the scaled Kyte and Doolittle measurement of hydropathy [<xref rid="pone.0266929.ref033" ref-type="bibr">33</xref>]. (E) IUPred2 predicts a C-terminal IDR in GCNA [<xref rid="pone.0266929.ref023" ref-type="bibr">23</xref>, <xref rid="pone.0266929.ref024" ref-type="bibr">24</xref>]. Residues with a score 0.0â0.5 are predicted to be ordered, regions 0.5â1.0 are predicted to be disordered. (F) FoldIndex predicts a C-terminal IDR in GCNA [<xref rid="pone.0266929.ref036" ref-type="bibr">36</xref>]. Residues with a score 0.0 â+1.0 are predicted to be ordered, regions -1.0â0.0 are predicted to be disordered.</p>
        </caption>
        <graphic xlink:href="pone.0266929.g003" position="float"/>
      </fig>
    </sec>
  </sec>
  <sec sec-type="conclusions" id="sec014">
    <title>Conclusion</title>
    <p>We have created an integrated R package that combines disorder prediction tools, hydropathy, and amino acid composition to facilitate the characterization of IDPs. The presence of charge repulsion and hydrophobic deficiencies are hallmark characteristics of an IDP or IDR [<xref rid="pone.0266929.ref018" ref-type="bibr">18</xref>]. The <italic toggle="yes">idpr</italic> package contains distinct, customizable methods for calculating charge and hydropathy for a protein sequence of interest. The output is a visually accessible, graphical readout of critical parameter for IDP analysis. We have validated the use of this tool with Î±-Synuclein, p53, and GCNA.</p>
    <p>A significant portion of the eukaryotic proteome is thought to contain IDRs, but our understanding of these domains is still lacking. In some cases, these domains serve as bridges between two structured domains [<xref rid="pone.0266929.ref074" ref-type="bibr">74</xref>]. In others, like p53, the IDR attains different structure with unique protein partners [<xref rid="pone.0266929.ref003" ref-type="bibr">3</xref>, <xref rid="pone.0266929.ref075" ref-type="bibr">75</xref>]. Yet in others, the IDRs support liquid-liquid phase separation [<xref rid="pone.0266929.ref076" ref-type="bibr">76</xref>]. In most cases, the role of the IDR is unknown. By providing an integrative tool for characterization of these domains, we envision <italic toggle="yes">idpr</italic> as platform upon which to find commonalities between IDPs and all for sub-division of these protein families.</p>
  </sec>
  <sec id="sec015" sec-type="supplementary-material">
    <title>Supporting information</title>
    <supplementary-material id="pone.0266929.s001" position="float" content-type="local-data">
      <label>S1 File</label>
      <caption>
        <title>This contains a list of abbreviations and S1 and S2 Figs.</title>
        <p>(DOCX)</p>
      </caption>
      <media xlink:href="pone.0266929.s001.docx">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
    <supplementary-material id="pone.0266929.s002" position="float" content-type="local-data">
      <label>S2 File</label>
      <caption>
        <title>The code used to generate all graphics presented in this manuscript.</title>
        <p>(PDF)</p>
      </caption>
      <media xlink:href="pone.0266929.s002.pdf">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
  </sec>
</body>
<back>
  <ack>
    <p>We would like to acknowledge the support of Dr. Michael Buszczak during the development of the package. Additionally, we would like to thank Dr. Miguel BrieÃ±o-EnrÃ­quez and the members of the BrieÃ±o-EnrÃ­quez and Yanowitz labs for feedback during package development. For providing essential details in making the package, we would like to acknowledge the book <italic toggle="yes">R Packages</italic> by Hadley Wickham (OâReilly) Â©2015 Hadley Wickham, ISBN: 978-1-491-91059-7.</p>
  </ack>
  <ref-list>
    <title>References</title>
    <ref id="pone.0266929.ref001">
      <label>1</label>
      <mixed-citation publication-type="journal"><name><surname>Dunker</surname><given-names>AK</given-names></name>, <name><surname>Lawson</surname><given-names>JD</given-names></name>, <name><surname>Brown</surname><given-names>CJ</given-names></name>, <name><surname>Williams</surname><given-names>RM</given-names></name>, <name><surname>Romero</surname><given-names>P</given-names></name>, <name><surname>Oh</surname><given-names>JS</given-names></name>, <etal>et al</etal>. <article-title>Intrinsically disordered protein</article-title>. <source>Journal of Molecular Graphics and Modelling</source>. <year>2001</year>;<volume>19</volume>(<issue>11</issue>):<fpage>26</fpage>â<lpage>59</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/s1093-3263(00)00138-8</pub-id><?supplied-pmid 11381529?><pub-id pub-id-type="pmid">11381529</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0266929.ref002">
      <label>2</label>
      <mixed-citation publication-type="journal"><name><surname>Tompa</surname><given-names>P.</given-names></name><article-title>Intrinsically unstructured proteins</article-title>. <source>Trends in biochemical sciences</source>. <year>2002</year>;<volume>27</volume>(<issue>10</issue>):<fpage>527</fpage>â<lpage>33</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/s0968-0004(02)02169-2</pub-id><?supplied-pmid 12368089?><pub-id pub-id-type="pmid">12368089</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0266929.ref003">
      <label>3</label>
      <mixed-citation publication-type="journal"><name><surname>Uversky</surname><given-names>VN</given-names></name>. <article-title>Intrinsically disordered proteins from A to Z.</article-title><source>The International Journal of Biochemistry &amp; Cell Biology</source>. <year>2011</year>;<volume>43</volume>(<issue>8</issue>):<fpage>1090</fpage>â<lpage>103</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.biocel.2011.04.001</pub-id><?supplied-pmid 21501695?><pub-id pub-id-type="pmid">21501695</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0266929.ref004">
      <label>4</label>
      <mixed-citation publication-type="journal"><name><surname>Wright</surname><given-names>PE</given-names></name>, <name><surname>Dyson</surname><given-names>HJ</given-names></name>. <article-title>Intrinsically unstructured proteins: re-assessing the protein structure-function paradigm</article-title>. <source>Journal of Molecular Biology</source>. <year>1999</year>;<volume>293</volume>(<issue>22</issue>):<fpage>321</fpage>â<lpage>31</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1006/jmbi.1999.3110</pub-id><?supplied-pmid 10550212?><pub-id pub-id-type="pmid">10550212</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0266929.ref005">
      <label>5</label>
      <mixed-citation publication-type="journal"><name><surname>Uversky</surname><given-names>VN</given-names></name>, <name><surname>Oldfield</surname><given-names>CJ</given-names></name>, <name><surname>Midic</surname><given-names>U</given-names></name>, <name><surname>Xie</surname><given-names>H</given-names></name>, <name><surname>Xue</surname><given-names>B</given-names></name>, <name><surname>Vucetic</surname><given-names>S</given-names></name>, <etal>et al</etal>. <article-title>Unfoldomics of human diseases: linking protein intrinsic disorder with diseases</article-title>. <source>BMC Genomics</source>. <year>2009</year>;<volume>10</volume>(<issue>11</issue>):<fpage>S7</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1186/1471-2164-10-S1-S7</pub-id><?supplied-pmid 19594884?><pub-id pub-id-type="pmid">19594884</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0266929.ref006">
      <label>6</label>
      <mixed-citation publication-type="journal"><name><surname>Uversky</surname><given-names>VN</given-names></name>, <name><surname>Oldfield</surname><given-names>CJ</given-names></name>, <name><surname>Dunker</surname><given-names>AK</given-names></name>. <article-title>Intrinsically disordered proteins in human diseases: introducing the D2 concept</article-title>. <source>Annu Rev Biophys</source>. <year>2008</year>;<volume>37</volume>:<fpage>215</fpage>â<lpage>46</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1146/annurev.biophys.37.032807.125924</pub-id><?supplied-pmid 18573080?><pub-id pub-id-type="pmid">18573080</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0266929.ref007">
      <label>7</label>
      <mixed-citation publication-type="journal"><name><surname>Radivojac</surname><given-names>P</given-names></name>, <name><surname>Iakoucheva</surname><given-names>LM</given-names></name>, <name><surname>Oldfield</surname><given-names>CJ</given-names></name>, <name><surname>Obradovic</surname><given-names>Z</given-names></name>, <name><surname>Uversky</surname><given-names>VN</given-names></name>, <name><surname>Dunker</surname><given-names>AK</given-names></name>. <article-title>Intrinsic Disorder and Functional Proteomics.</article-title><source>Biophysical Journal</source>. <year>2007</year>;<volume>92</volume>(<issue>55</issue>):<fpage>1439</fpage>â<lpage>56</lpage>.<pub-id pub-id-type="pmid">17158572</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0266929.ref008">
      <label>8</label>
      <mixed-citation publication-type="journal"><name><surname>Pancsa</surname><given-names>R</given-names></name>, <name><surname>Tompa</surname><given-names>P</given-names></name>. <article-title>Structural disorder in eukaryotes</article-title>. <source>PLoS One</source>. <year>2012</year>;<volume>7</volume>(<issue>44</issue>):<fpage>e34687</fpage>âe. <comment>doi: </comment><pub-id pub-id-type="doi">10.1371/journal.pone.0034687</pub-id><?supplied-pmid 22496841?><pub-id pub-id-type="pmid">22496841</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0266929.ref009">
      <label>9</label>
      <mixed-citation publication-type="journal"><name><surname>Xue</surname><given-names>B</given-names></name>, <name><surname>Dunker</surname><given-names>AK</given-names></name>, <name><surname>Uversky</surname><given-names>VN</given-names></name>. <article-title>Orderly order in protein intrinsic disorder distribution: disorder in 3500 proteomes from viruses and the three domains of life</article-title>. <source>Journal of Biomolecular Structure and Dynamics</source>. <year>2012</year>;<volume>30</volume>(<issue>22</issue>):<fpage>137</fpage>â<lpage>49</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1080/07391102.2012.675145</pub-id><?supplied-pmid 22702725?><pub-id pub-id-type="pmid">22702725</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0266929.ref010">
      <label>10</label>
      <mixed-citation publication-type="journal"><name><surname>Kulkarni</surname><given-names>P</given-names></name>, <name><surname>Uversky</surname><given-names>VN</given-names></name>. <article-title>Intrinsically Disordered Proteins: The Dark Horse of the Dark Proteome</article-title>. <source>PROTEOMICS</source>. <year>2018</year>;<volume>18</volume>(<issue>21â22</issue>):<fpage>1800061</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1002/pmic.201800061</pub-id><?supplied-pmid 30218496?><pub-id pub-id-type="pmid">30218496</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0266929.ref011">
      <label>11</label>
      <mixed-citation publication-type="journal"><name><surname>Niklas</surname><given-names>KJ</given-names></name>, <name><surname>Dunker</surname><given-names>AK</given-names></name>, <name><surname>Yruela</surname><given-names>I</given-names></name>. <article-title>The evolutionary origins of cell type diversification and the role of intrinsically disordered proteins</article-title>. <source>Journal of Experimental Botany</source>. <year>2018</year>;<volume>69</volume>(<issue>77</issue>):<fpage>1437</fpage>â<lpage>46</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/jxb/erx493</pub-id><?supplied-pmid 29394379?><pub-id pub-id-type="pmid">29394379</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0266929.ref012">
      <label>12</label>
      <mixed-citation publication-type="journal"><name><surname>Kurgan</surname><given-names>L</given-names></name>, <name><surname>Radivojac</surname><given-names>P</given-names></name>, <name><surname>Sussman</surname><given-names>JL</given-names></name>, <name><surname>Dunker</surname><given-names>AK</given-names></name>. <article-title>On the Importance of Computational Biology and Bioinformatics to the Origins and Rapid Progression of the Intrinsically Disordered Proteins Field.</article-title><source>Biocomputing</source><year>2020</year>. <volume>2019</volume>:<fpage>149</fpage>â<lpage>58</lpage>.</mixed-citation>
    </ref>
    <ref id="pone.0266929.ref013">
      <label>13</label>
      <mixed-citation publication-type="journal"><name><surname>Li</surname><given-names>J</given-names></name>, <name><surname>Feng</surname><given-names>Y</given-names></name>, <name><surname>Wang</surname><given-names>X</given-names></name>, <name><surname>Li</surname><given-names>J</given-names></name>, <name><surname>Liu</surname><given-names>W</given-names></name>, <name><surname>Rong</surname><given-names>L</given-names></name>, <etal>et al</etal>. <article-title>An Overview of Predictors for Intrinsically Disordered Proteins over 2010â2014.</article-title><source>Int J Mol Sci</source>. <year>2015</year>;<volume>16</volume>(<issue>10</issue>):<fpage>23446</fpage>â<lpage>62</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3390/ijms161023446</pub-id><?supplied-pmid 26426014?><pub-id pub-id-type="pmid">26426014</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0266929.ref014">
      <label>14</label>
      <mixed-citation publication-type="journal"><name><surname>Meng</surname><given-names>F</given-names></name>, <name><surname>Uversky</surname><given-names>V</given-names></name>, <name><surname>Kurgan</surname><given-names>L</given-names></name>. <article-title>Computational prediction of intrinsic disorder in proteins</article-title>. <source>Current protocols in protein science</source>. <year>2017</year>;<volume>88</volume>(<issue>11</issue>):<fpage>2.16.01</fpage>â<lpage>14</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1002/cpps.28</pub-id><?supplied-pmid 28369666?><pub-id pub-id-type="pmid">28369666</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0266929.ref015">
      <label>15</label>
      <mixed-citation publication-type="journal"><name><surname>Liu</surname><given-names>Y</given-names></name>, <name><surname>Wang</surname><given-names>X</given-names></name>, <name><surname>Liu</surname><given-names>B</given-names></name>. <article-title>A comprehensive review and comparison of existing computational methods for intrinsically disordered protein and region prediction</article-title>. <source>Briefings in Bioinformatics</source>. <year>2017</year>;<volume>20</volume>(<issue>11</issue>):<fpage>330</fpage>â<lpage>46</lpage>.</mixed-citation>
    </ref>
    <ref id="pone.0266929.ref016">
      <label>16</label>
      <mixed-citation publication-type="journal"><name><surname>Uversky</surname><given-names>VN</given-names></name>, <name><surname>Gillespie</surname><given-names>JR</given-names></name>, <name><surname>Fink</surname><given-names>AL</given-names></name>. <article-title>Why are ânatively unfoldedâ proteins unstructured under physiologic conditions?</article-title><source>Proteins: Structure, Function, and Bioinformatics</source>. <year>2000</year>;<volume>41</volume>(<issue>33</issue>):<fpage>415</fpage>â<lpage>27</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1002/1097-0134(20001115)41:3&amp;lt;415::aid-prot130&amp;gt;3.0.co;2-7</pub-id><?supplied-pmid 11025552?><pub-id pub-id-type="pmid">11025552</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0266929.ref017">
      <label>17</label>
      <mixed-citation publication-type="journal"><name><surname>Brown</surname><given-names>CJ</given-names></name>, <name><surname>Takayama</surname><given-names>S</given-names></name>, <name><surname>Campen</surname><given-names>AM</given-names></name>, <name><surname>Vise</surname><given-names>P</given-names></name>, <name><surname>Marshall</surname><given-names>TW</given-names></name>, <name><surname>Oldfield</surname><given-names>CJ</given-names></name>, <etal>et al</etal>. <article-title>Evolutionary rate heterogeneity in proteins with long disordered regions</article-title>. <source>Journal of molecular evolution</source>. <year>2002</year>;<volume>55</volume>(<issue>11</issue>):<fpage>104</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1007/s00239-001-2309-6</pub-id><?supplied-pmid 12165847?><pub-id pub-id-type="pmid">12165847</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0266929.ref018">
      <label>18</label>
      <mixed-citation publication-type="journal"><name><surname>Uversky</surname><given-names>VN</given-names></name>. <article-title>Intrinsically Disordered Proteins and Their âMysteriousâ (Meta)Physics.</article-title><source>Frontiers in Physics</source>. <year>2019</year>;<volume>7</volume>(<issue>10</issue>).</mixed-citation>
    </ref>
    <ref id="pone.0266929.ref019">
      <label>19</label>
      <mixed-citation publication-type="journal"><name><surname>Forcelloni</surname><given-names>S</given-names></name>, <name><surname>Giansanti</surname><given-names>A</given-names></name>. <article-title>Evolutionary Forces and Codon Bias in Different Flavors of Intrinsic Disorder in the Human Proteome</article-title>. <source>Journal of Molecular Evolution</source>. <year>2020</year>;<volume>88</volume>(<issue>22</issue>):<fpage>164</fpage>â<lpage>78</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1007/s00239-019-09921-4</pub-id><?supplied-pmid 31820049?><pub-id pub-id-type="pmid">31820049</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0266929.ref020">
      <label>20</label>
      <mixed-citation publication-type="journal"><name><surname>Trivedi</surname><given-names>R</given-names></name>, <name><surname>Nagarajaram</surname><given-names>HA</given-names></name>. <article-title>Amino acid substitution scoring matrices specific to intrinsically disordered regions in proteins</article-title>. <source>Scientific Reports</source>. <year>2019</year>;<volume>911</volume>):<fpage>16380</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/s41598-019-52532-8</pub-id><?supplied-pmid 31704957?><pub-id pub-id-type="pmid">31704957</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0266929.ref021">
      <label>21</label>
      <mixed-citation publication-type="journal"><name><surname>Brown</surname><given-names>CJ</given-names></name>, <name><surname>Johnson</surname><given-names>AK</given-names></name>, <name><surname>Daughdrill</surname><given-names>GW</given-names></name>. <article-title>Comparing Models of Evolution for Ordered and Disordered Proteins</article-title>. <source>Molecular Biology and Evolution</source>. <year>2009</year>;<volume>27</volume>[<issue>33</issue>]:<fpage>609</fpage>â<lpage>21</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/molbev/msp277</pub-id><?supplied-pmid 19923193?><pub-id pub-id-type="pmid">19923193</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0266929.ref022">
      <label>22</label>
      <mixed-citation publication-type="journal"><name><surname>Radivojac</surname><given-names>P</given-names></name>, <name><surname>Obradovic</surname><given-names>Z</given-names></name>, <name><surname>Brown</surname><given-names>CJ</given-names></name>, <name><surname>Dunker</surname><given-names>AK</given-names></name>. <article-title>Improving sequence alignments for intrinsically disordered proteins</article-title>. <source>Biocomputing 2002: World Scientific</source>; <year>2001</year>. p. <fpage>589</fpage>â<lpage>600</lpage>.</mixed-citation>
    </ref>
    <ref id="pone.0266929.ref023">
      <label>23</label>
      <mixed-citation publication-type="journal"><name><surname>MÃ©szÃ¡ros</surname><given-names>B</given-names></name>, <name><surname>ErdÅs</surname><given-names>G</given-names></name>, <name><surname>DosztÃ¡nyi</surname><given-names>Z</given-names></name>. <article-title>IUPred2A: context-dependent prediction of protein disorder as a function of redox state and protein binding</article-title>. <source>Nucleic acids research</source>. <year>2018</year>;<volume>46</volume>(<issue>W1</issue>):<fpage>W329</fpage>â<lpage>W37</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/nar/gky384</pub-id><?supplied-pmid 29860432?><pub-id pub-id-type="pmid">29860432</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0266929.ref024">
      <label>24</label>
      <mixed-citation publication-type="journal"><name><surname>ErdÅs</surname><given-names>G</given-names></name>, <name><surname>DosztÃ¡nyi</surname><given-names>Z</given-names></name>. <article-title>Analyzing Protein Disorder with IUPred2A.</article-title><source>Current Protocols in Bioinformatics</source>. <year>2020</year>;<volume>70</volume>(<issue>11</issue>):<fpage>e99</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1002/cpbi.99</pub-id><?supplied-pmid 32237272?><pub-id pub-id-type="pmid">32237272</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0266929.ref025">
      <label>25</label>
      <mixed-citation publication-type="book"><name><surname>Wickham</surname><given-names>H.</given-names></name><part-title>ggplot2: elegant graphics for data analysis</part-title>. <publisher-loc>New York</publisher-loc>: <publisher-name>Springer-Verlag</publisher-name>; <year>2016</year>.</mixed-citation>
    </ref>
    <ref id="pone.0266929.ref026">
      <label>26</label>
      <mixed-citation publication-type="book"><collab>R Core Team</collab>. <part-title>R: A language and environment for statistical computing</part-title>. <edition>3.6.1 ed.</edition><publisher-loc>Vienna, Austria</publisher-loc>: <publisher-name>R Foundation for Statistical Computing</publisher-name>,; <year>2019</year>.</mixed-citation>
    </ref>
    <ref id="pone.0266929.ref027">
      <label>27</label>
      <mixed-citation publication-type="journal"><name><surname>Gentleman</surname><given-names>RC</given-names></name>, <name><surname>Carey</surname><given-names>VJ</given-names></name>, <name><surname>Bates</surname><given-names>DM</given-names></name>, <name><surname>Bolstad</surname><given-names>B</given-names></name>, <name><surname>Dettling</surname><given-names>M</given-names></name>, <name><surname>Dudoit</surname><given-names>S</given-names></name>, <etal>et al</etal>. <article-title>Bioconductor: open software development for computational biology and bioinformatics</article-title>. <source>Genome biology</source>. <year>2004</year>;<volume>5</volume>(<issue>10</issue>):<fpage>R80</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1186/gb-2004-5-10-r80</pub-id><?supplied-pmid 15461798?><pub-id pub-id-type="pmid">15461798</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0266929.ref028">
      <label>28</label>
      <mixed-citation publication-type="journal"><name><surname>PagÃ¨s</surname><given-names>H</given-names></name>, <name><surname>Aboyoun</surname><given-names>P</given-names></name>, <name><surname>Gentleman</surname><given-names>R</given-names></name>, <name><surname>DebRoy</surname><given-names>S</given-names></name>. <article-title>Biostrings: Efficient manipulation of biological strings</article-title>. <source>R package version 2.60.1</source>. <year>2021</year>.</mixed-citation>
    </ref>
    <ref id="pone.0266929.ref029">
      <label>29</label>
      <mixed-citation publication-type="journal"><name><surname>Ooms</surname><given-names>J.</given-names></name><article-title>The jsonlite package: A practical and consistent mapping between json data and r objects</article-title>. <source>arXiv [Preprint] arXiv:14032805</source>. <year>2014</year>.</mixed-citation>
    </ref>
    <ref id="pone.0266929.ref030">
      <label>30</label>
      <mixed-citation publication-type="journal"><name><surname>Wickham</surname><given-names>H</given-names></name>, <name><surname>Averick</surname><given-names>M</given-names></name>, <name><surname>Bryan</surname><given-names>J</given-names></name>, <name><surname>Chang</surname><given-names>W</given-names></name>, <name><surname>McGowan</surname><given-names>LDA</given-names></name>, <name><surname>FranÃ§ois</surname><given-names>R</given-names></name>, <etal>et al</etal>. <article-title>Welcome to the Tidyverse.</article-title><source>Journal of open source software</source>. <year>2019</year>;<volume>4</volume>(<issue>43</issue>):<fpage>1686</fpage>.</mixed-citation>
    </ref>
    <ref id="pone.0266929.ref031">
      <label>31</label>
      <mixed-citation publication-type="journal"><name><surname>Wickham</surname><given-names>H</given-names></name>, <name><surname>Danenberg</surname><given-names>P</given-names></name>, <name><surname>CsÃ¡rdi</surname><given-names>G</given-names></name>, <name><surname>Eugster</surname><given-names>M</given-names></name>. <article-title>roxygen2: In-Line Documentation for R</article-title>. <source>R Package version 7.1.1</source>. <year>2020</year>.</mixed-citation>
    </ref>
    <ref id="pone.0266929.ref032">
      <label>32</label>
      <mixed-citation publication-type="journal"><name><surname>Morgan</surname><given-names>M.</given-names></name><article-title>BiocManager: access the Bioconductor project package repository</article-title>. <source>R package version 1.30.16</source>. <year>2021</year>.</mixed-citation>
    </ref>
    <ref id="pone.0266929.ref033">
      <label>33</label>
      <mixed-citation publication-type="journal"><name><surname>Kyte</surname><given-names>J</given-names></name>, <name><surname>Doolittle</surname><given-names>RF</given-names></name>. <article-title>A simple method for displaying the hydropathic character of a protein</article-title>. <source>Journal of molecular biology</source>. <year>1982</year>;<volume>157</volume>(<issue>11</issue>):<fpage>105</fpage>â<lpage>32</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/0022-2836(82)90515-0</pub-id><?supplied-pmid 7108955?><pub-id pub-id-type="pmid">7108955</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0266929.ref034">
      <label>34</label>
      <mixed-citation publication-type="journal"><name><surname>Kozlowski</surname><given-names>LP</given-names></name>. <article-title>IPCâIsoelectric Point Calculator.</article-title><source>Biology Direct</source>. <year>2016</year>;<volume>11</volume>(<issue>11</issue>):<fpage>55</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1186/s13062-016-0159-9</pub-id><?supplied-pmid 27769290?><pub-id pub-id-type="pmid">27769290</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0266929.ref035">
      <label>35</label>
      <mixed-citation publication-type="journal"><name><surname>Uversky</surname><given-names>VN</given-names></name>. <article-title>Unusual biophysics of intrinsically disordered proteins</article-title>. <source>Biochimica et Biophysica Acta (BBA)âProteins and Proteomics</source>. <year>2013</year>;<volume>1834</volume>(<issue>55</issue>):<fpage>932</fpage>â<lpage>51</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.bbapap.2012.12.008</pub-id><?supplied-pmid 23269364?><pub-id pub-id-type="pmid">23269364</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0266929.ref036">
      <label>36</label>
      <mixed-citation publication-type="journal"><name><surname>Prilusky</surname><given-names>J</given-names></name>, <name><surname>Felder</surname><given-names>CE</given-names></name>, <name><surname>Zeev-Ben-Mordehai</surname><given-names>T</given-names></name>, <name><surname>Rydberg</surname><given-names>EH</given-names></name>, <name><surname>Man</surname><given-names>O</given-names></name>, <name><surname>Beckmann</surname><given-names>JS</given-names></name>, <etal>et al</etal>. <article-title>FoldIndexÂ©: a simple tool to predict whether a given protein sequence is intrinsically unfolded</article-title>. <source>Bioinformatics</source>. <year>2005</year>;<volume>21</volume>(<issue>16</issue>):<fpage>3435</fpage>â<lpage>8</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/bioinformatics/bti537</pub-id><?supplied-pmid 15955783?><pub-id pub-id-type="pmid">15955783</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0266929.ref037">
      <label>37</label>
      <mixed-citation publication-type="journal"><name><surname>Uversky</surname><given-names>VN</given-names></name>. <article-title>Paradoxes and wonders of intrinsic disorder: Complexity of simplicity</article-title>. <source>Intrinsically Disordered Proteins</source>. <year>2016</year>;<volume>4</volume>(<issue>11</issue>):<fpage>e1135015</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1080/21690707.2015.1135015</pub-id><?supplied-pmid 28232895?><pub-id pub-id-type="pmid">28232895</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0266929.ref038">
      <label>38</label>
      <mixed-citation publication-type="journal"><name><surname>Po</surname><given-names>HN</given-names></name>, <name><surname>Senozan</surname><given-names>N</given-names></name>. <article-title>The Henderson-Hasselbalch equation: its history and limitations</article-title>. <source>Journal of Chemical Education</source>. <year>2001</year>;<volume>78</volume>(<issue>11</issue>):<fpage>1499</fpage>.</mixed-citation>
    </ref>
    <ref id="pone.0266929.ref039">
      <label>39</label>
      <mixed-citation publication-type="journal"><name><surname>Gasteiger</surname><given-names>E</given-names></name>, <name><surname>Hoogland</surname><given-names>C</given-names></name>, <name><surname>Gattiker</surname><given-names>A</given-names></name>, <name><surname>Wilkins</surname><given-names>MR</given-names></name>, <name><surname>Appel</surname><given-names>RD</given-names></name>, <name><surname>Bairoch</surname><given-names>A</given-names></name>. <article-title>Protein identification and analysis tools on the ExPASy server</article-title>. <source>The proteomics protocols handbook: Springer</source>; <year>2005</year>. p. <fpage>571</fpage>â<lpage>607</lpage>.</mixed-citation>
    </ref>
    <ref id="pone.0266929.ref040">
      <label>40</label>
      <mixed-citation publication-type="journal"><name><surname>Theillet</surname><given-names>F-X</given-names></name>, <name><surname>Kalmar</surname><given-names>L</given-names></name>, <name><surname>Tompa</surname><given-names>P</given-names></name>, <name><surname>Han</surname><given-names>K-H</given-names></name>, <name><surname>Selenko</surname><given-names>P</given-names></name>, <name><surname>Dunker</surname><given-names>AK</given-names></name>, <etal>et al</etal>. <article-title>The alphabet of intrinsic disorder: I. Act like a Pro: On the abundance and roles of proline residues in intrinsically disordered proteins.</article-title><source>Intrinsically disordered proteins</source>. <year>2013</year>;<volume>1</volume>(<issue>11</issue>):<fpage>e24360</fpage>âe.<pub-id pub-id-type="pmid">28516008</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0266929.ref041">
      <label>41</label>
      <mixed-citation publication-type="journal"><name><surname>DosztÃ¡nyi</surname><given-names>Z.</given-names></name><article-title>Prediction of protein disorder based on IUPred</article-title>. <source>Protein Sci</source>. <year>2018</year>;<volume>27</volume>(<issue>11</issue>):<fpage>331</fpage>â<lpage>40</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1002/pro.3334</pub-id><?supplied-pmid 29076577?><pub-id pub-id-type="pmid">29076577</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0266929.ref042">
      <label>42</label>
      <mixed-citation publication-type="journal"><name><surname>Sun</surname><given-names>Y</given-names></name>, <name><surname>Oberley</surname><given-names>LW</given-names></name>. <article-title>Redox regulation of transcriptional activators</article-title>. <source>Free Radical Biology and Medicine</source>. <year>1996</year>;<volume>21</volume>(<issue>33</issue>):<fpage>335</fpage>â<lpage>48</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/0891-5849(96)00109-8</pub-id><?supplied-pmid 8855444?><pub-id pub-id-type="pmid">8855444</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0266929.ref043">
      <label>43</label>
      <mixed-citation publication-type="journal"><name><surname>Franzosa</surname><given-names>EA</given-names></name>, <name><surname>Xia</surname><given-names>Y</given-names></name>. <article-title>Structural Determinants of Protein Evolution Are Context-Sensitive at the Residue Level</article-title>. <source>Molecular Biology and Evolution</source>. <year>2009</year>;<volume>26</volume>(<issue>10</issue>):<fpage>2387</fpage>â<lpage>95</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/molbev/msp146</pub-id><?supplied-pmid 19597162?><pub-id pub-id-type="pmid">19597162</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0266929.ref044">
      <label>44</label>
      <mixed-citation publication-type="journal"><name><surname>Dayhoff</surname><given-names>M</given-names></name>, <name><surname>Schwartz</surname><given-names>R</given-names></name>, <name><surname>Orcutt</surname><given-names>B</given-names></name>. <article-title>22 a model of evolutionary change in proteins. Atlas of protein sequence and structure.</article-title><source>5: National Biomedical Research Foundation Silver Spring MD</source>; <year>1978</year>. p. <fpage>345</fpage>â<lpage>52</lpage>.</mixed-citation>
    </ref>
    <ref id="pone.0266929.ref045">
      <label>45</label>
      <mixed-citation publication-type="journal"><name><surname>Henikoff</surname><given-names>S</given-names></name>, <name><surname>Henikoff</surname><given-names>JG</given-names></name>. <article-title>Amino acid substitution matrices from protein blocks</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>1992</year>;<volume>89</volume>(<issue>22</issue>):<fpage>10915</fpage>â<lpage>9</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1073/pnas.89.22.10915</pub-id><?supplied-pmid 1438297?><pub-id pub-id-type="pmid">1438297</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0266929.ref046">
      <label>46</label>
      <mixed-citation publication-type="journal"><name><surname>Johnson</surname><given-names>M</given-names></name>, <name><surname>Zaretskaya</surname><given-names>I</given-names></name>, <name><surname>Raytselis</surname><given-names>Y</given-names></name>, <name><surname>Merezhuk</surname><given-names>Y</given-names></name>, <name><surname>McGinnis</surname><given-names>S</given-names></name>, <name><surname>Madden</surname><given-names>TL</given-names></name>. <article-title>NCBI BLAST: a better web interface</article-title>. <source>Nucleic Acids Research</source>. <year>2008</year>;<volume>36</volume>(<issue>suppl_2</issue>):<fpage>W5</fpage>â<lpage>W9</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/nar/gkn201</pub-id><?supplied-pmid 18440982?><pub-id pub-id-type="pmid">18440982</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0266929.ref047">
      <label>47</label>
      <mixed-citation publication-type="journal"><name><surname>Madeira</surname><given-names>F</given-names></name>, <name><surname>Park</surname><given-names>YM</given-names></name>, <name><surname>Lee</surname><given-names>J</given-names></name>, <name><surname>Buso</surname><given-names>N</given-names></name>, <name><surname>Gur</surname><given-names>T</given-names></name>, <name><surname>Madhusoodanan</surname><given-names>N</given-names></name>, <etal>et al</etal>. <article-title>The EMBL-EBI search and sequence analysis tools APIs in 2019</article-title>. <source>Nucleic acids research</source>. <year>2019</year>;<volume>47</volume>(<issue>W1</issue>):<fpage>W636</fpage>â<lpage>W41</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/nar/gkz268</pub-id><?supplied-pmid 30976793?><pub-id pub-id-type="pmid">30976793</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0266929.ref048">
      <label>48</label>
      <mixed-citation publication-type="journal"><name><surname>Weinreb</surname><given-names>PH</given-names></name>, <name><surname>Zhen</surname><given-names>W</given-names></name>, <name><surname>Poon</surname><given-names>AW</given-names></name>, <name><surname>Conway</surname><given-names>KA</given-names></name>, <name><surname>Lansbury</surname><given-names>PT</given-names></name>. <article-title>NACP, a protein implicated in Alzheimerâs disease and learning, is natively unfolded</article-title>. <source>Biochemistry</source>. <year>1996</year>;<volume>35</volume>(<issue>43</issue>):<fpage>13709</fpage>â<lpage>15</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1021/bi961799n</pub-id><?supplied-pmid 8901511?><pub-id pub-id-type="pmid">8901511</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0266929.ref049">
      <label>49</label>
      <mixed-citation publication-type="journal"><name><surname>Theillet</surname><given-names>F-X</given-names></name>, <name><surname>Binolfi</surname><given-names>A</given-names></name>, <name><surname>Bekei</surname><given-names>B</given-names></name>, <name><surname>Martorana</surname><given-names>A</given-names></name>, <name><surname>Rose</surname><given-names>HM</given-names></name>, <name><surname>Stuiver</surname><given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Structural disorder of monomeric Î±-synuclein persists in mammalian cells</article-title>. <source>Nature</source>. <year>2016</year>;<volume>530</volume>(<issue>7588</issue>):<fpage>45</fpage>â<lpage>50</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/nature16531</pub-id><?supplied-pmid 26808899?><pub-id pub-id-type="pmid">26808899</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0266929.ref050">
      <label>50</label>
      <mixed-citation publication-type="journal"><name><surname>Fauvet</surname><given-names>B</given-names></name>, <name><surname>Mbefo</surname><given-names>MK</given-names></name>, <name><surname>Fares</surname><given-names>M-B</given-names></name>, <name><surname>Desobry</surname><given-names>C</given-names></name>, <name><surname>Michael</surname><given-names>S</given-names></name>, <name><surname>Ardah</surname><given-names>MT</given-names></name>, <etal>et al</etal>. <article-title>Î±-Synuclein in central nervous system and from erythrocytes, mammalian cells, and Escherichia coli exists predominantly as disordered monomer</article-title>. <source>J Biol Chem</source>. <year>2012</year>;<volume>287</volume>(<issue>19</issue>):<fpage>15345</fpage>â<lpage>64</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1074/jbc.M111.318949</pub-id><?supplied-pmid 22315227?><pub-id pub-id-type="pmid">22315227</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0266929.ref051">
      <label>51</label>
      <mixed-citation publication-type="journal"><name><surname>Eliezer</surname><given-names>D</given-names></name>, <name><surname>Kutluay</surname><given-names>E</given-names></name>, <name><surname>Bussell</surname><given-names>R</given-names><suffix>Jr</suffix></name>, <name><surname>Browne</surname><given-names>G</given-names></name>. <article-title>Conformational properties of Î±-synuclein in its free and lipid-associated states</article-title>. <source>Journal of molecular biology</source>. <year>2001</year>;<volume>307</volume>(<issue>44</issue>):<fpage>1061</fpage>â<lpage>73</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1006/jmbi.2001.4538</pub-id><?supplied-pmid 11286556?><pub-id pub-id-type="pmid">11286556</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0266929.ref052">
      <label>52</label>
      <mixed-citation publication-type="journal"><name><surname>Kim</surname><given-names>D-H</given-names></name>, <name><surname>Lee</surname><given-names>J</given-names></name>, <name><surname>Mok</surname><given-names>KH</given-names></name>, <name><surname>Lee</surname><given-names>JH</given-names></name>, <name><surname>Han</surname><given-names>K-H</given-names></name>. <article-title>Salient Features of Monomeric Alpha-Synuclein Revealed by NMR Spectroscopy.</article-title><source>Biomolecules</source>. <year>2020</year>;<volume>10</volume>(<issue>33</issue>):<fpage>428</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3390/biom10030428</pub-id><?supplied-pmid 32164323?><pub-id pub-id-type="pmid">32164323</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0266929.ref053">
      <label>53</label>
      <mixed-citation publication-type="journal"><name><surname>LÃ¼cking</surname><given-names>CB</given-names></name>, <name><surname>Brice</surname><given-names>A</given-names></name>. <article-title>Alpha-synuclein and Parkinsonâs disease</article-title>. <source>Cellular and Molecular Life Sciences CMLS</source>. <year>2000</year>;<volume>57</volume>(<issue>13</issue>):<fpage>1894</fpage>â<lpage>908</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1007/PL00000671</pub-id><?supplied-pmid 11215516?><pub-id pub-id-type="pmid">11215516</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0266929.ref054">
      <label>54</label>
      <mixed-citation publication-type="journal"><name><surname>Xu</surname><given-names>L</given-names></name>, <name><surname>Pu</surname><given-names>J</given-names></name>. <article-title>Alpha-Synuclein in Parkinsonâs Disease: From Pathogenetic Dysfunction to Potential Clinical Application.</article-title><source>Parkinsonâs Disease</source>. <year>2016</year>;<volume>2016</volume>:<fpage>1720621</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1155/2016/1720621</pub-id><?supplied-pmid 27610264?><pub-id pub-id-type="pmid">27610264</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0266929.ref055">
      <label>55</label>
      <mixed-citation publication-type="journal"><name><surname>Kasten</surname><given-names>M</given-names></name>, <name><surname>Klein</surname><given-names>C</given-names></name>. <article-title>The many faces of alphaâsynuclein mutations</article-title>. <source>Movement Disorders</source>. <year>2013</year>;<volume>28</volume>(<issue>66</issue>):<fpage>697</fpage>â<lpage>701</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1002/mds.25499</pub-id><?supplied-pmid 23674458?><pub-id pub-id-type="pmid">23674458</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0266929.ref056">
      <label>56</label>
      <mixed-citation publication-type="journal"><name><surname>Flagmeier</surname><given-names>P</given-names></name>, <name><surname>Meisl</surname><given-names>G</given-names></name>, <name><surname>Vendruscolo</surname><given-names>M</given-names></name>, <name><surname>Knowles</surname><given-names>TPJ</given-names></name>, <name><surname>Dobson</surname><given-names>CM</given-names></name>, <name><surname>Buell</surname><given-names>AK</given-names></name>, <etal>et al</etal>. <article-title>Mutations associated with familial Parkinsonâs disease alter the initiation and amplification steps of Î±-synuclein aggregation</article-title>. <source>Proceedings of the National Academy of Sciences</source>. <year>2016</year>;<volume>113</volume>(<issue>37</issue>):<fpage>10328</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1073/pnas.1604645113</pub-id><?supplied-pmid 27573854?><pub-id pub-id-type="pmid">27573854</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0266929.ref057">
      <label>57</label>
      <mixed-citation publication-type="journal"><name><surname>Fujioka</surname><given-names>S</given-names></name>, <name><surname>Ogaki</surname><given-names>K</given-names></name>, <name><surname>Tacik</surname><given-names>PM</given-names></name>, <name><surname>Uitti</surname><given-names>RJ</given-names></name>, <name><surname>Ross</surname><given-names>OA</given-names></name>, <name><surname>Wszolek</surname><given-names>ZK</given-names></name>. <article-title>Update on novel familial forms of Parkinsonâs disease and multiple system atrophy.</article-title><source>Parkinsonism &amp; Related Disorders</source>. <year>2014</year>;<volume>20</volume>:<fpage>S29</fpage>â<lpage>S34</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/S1353-8020(13)70010-5</pub-id><?supplied-pmid 24262183?><pub-id pub-id-type="pmid">24262183</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0266929.ref058">
      <label>58</label>
      <mixed-citation publication-type="journal"><name><surname>Hollstein</surname><given-names>M</given-names></name>, <name><surname>Sidransky</surname><given-names>D</given-names></name>, <name><surname>Vogelstein</surname><given-names>B</given-names></name>, <name><surname>Harris</surname><given-names>CC</given-names></name>. <article-title>p53 mutations in human cancers</article-title>. <source>Science</source>. <year>1991</year>;<volume>253</volume>(<issue>5015</issue>):<fpage>49</fpage>â<lpage>53</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1126/science.1905840</pub-id><?supplied-pmid 1905840?><pub-id pub-id-type="pmid">1905840</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0266929.ref059">
      <label>59</label>
      <mixed-citation publication-type="journal"><name><surname>Surget</surname><given-names>S</given-names></name>, <name><surname>Khoury</surname><given-names>MP</given-names></name>, <name><surname>Bourdon</surname><given-names>J-C</given-names></name>. <article-title>Uncovering the role of p53 splice variants in human malignancy: a clinical perspective</article-title>. <source>OncoTargets and therapy</source>. <year>2014</year>;<volume>7</volume>:<fpage>57</fpage>.</mixed-citation>
    </ref>
    <ref id="pone.0266929.ref060">
      <label>60</label>
      <mixed-citation publication-type="journal"><name><surname>Kannan</surname><given-names>S</given-names></name>, <name><surname>Lane</surname><given-names>DP</given-names></name>, <name><surname>Verma</surname><given-names>CS</given-names></name>. <article-title>Long range recognition and selection in IDPs: the interactions of the C-terminus of p53</article-title>. <source>Scientific reports</source>. <year>2016</year>;<volume>6</volume>:<fpage>23750</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/srep23750</pub-id><?supplied-pmid 27030593?><pub-id pub-id-type="pmid">27030593</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0266929.ref061">
      <label>61</label>
      <mixed-citation publication-type="journal"><name><surname>Vise</surname><given-names>PD</given-names></name>, <name><surname>Baral</surname><given-names>B</given-names></name>, <name><surname>Latos</surname><given-names>AJ</given-names></name>, <name><surname>Daughdrill</surname><given-names>GW</given-names></name>. <article-title>NMR chemical shift and relaxation measurements provide evidence for the coupled folding and binding of the p53 transactivation domain</article-title>. <source>Nucleic acids research</source>. <year>2005</year>;<volume>33</volume>(<issue>77</issue>):<fpage>2061</fpage>â<lpage>77</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/nar/gki336</pub-id><?supplied-pmid 15824059?><pub-id pub-id-type="pmid">15824059</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0266929.ref062">
      <label>62</label>
      <mixed-citation publication-type="journal"><name><surname>Wells</surname><given-names>M</given-names></name>, <name><surname>Tidow</surname><given-names>H</given-names></name>, <name><surname>Rutherford</surname><given-names>TJ</given-names></name>, <name><surname>Markwick</surname><given-names>P</given-names></name>, <name><surname>Jensen</surname><given-names>MR</given-names></name>, <name><surname>Mylonas</surname><given-names>E</given-names></name>, <etal>et al</etal>. <article-title>Structure of tumor suppressor p53 and its intrinsically disordered N-terminal transactivation domain</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2008</year>;<volume>105</volume>(<issue>15</issue>):<fpage>5762</fpage>â<lpage>7</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1073/pnas.0801353105</pub-id><?supplied-pmid 18391200?><pub-id pub-id-type="pmid">18391200</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0266929.ref063">
      <label>63</label>
      <mixed-citation publication-type="journal"><name><surname>Sullivan</surname><given-names>KD</given-names></name>, <name><surname>Galbraith</surname><given-names>MD</given-names></name>, <name><surname>Andrysik</surname><given-names>Z</given-names></name>, <name><surname>Espinosa</surname><given-names>JM</given-names></name>. <article-title>Mechanisms of transcriptional regulation by p53. Cell Death &amp;</article-title><source>Differentiation</source>. <year>2018</year>;<volume>25</volume>(<issue>11</issue>):<fpage>133</fpage>â<lpage>43</lpage>.</mixed-citation>
    </ref>
    <ref id="pone.0266929.ref064">
      <label>64</label>
      <mixed-citation publication-type="journal"><name><surname>Buzek</surname><given-names>J</given-names></name>, <name><surname>Latonen</surname><given-names>L</given-names></name>, <name><surname>Kurki</surname><given-names>S</given-names></name>, <name><surname>Peltonen</surname><given-names>K</given-names></name>, <name><surname>Laiho</surname><given-names>M</given-names></name>. <article-title>Redox state of tumor suppressor p53 regulates its sequence-specific DNA binding in DNA-damaged cells by cysteine 277</article-title>. <source>Nucleic acids research</source>. <year>2002</year>;<volume>30</volume>(<issue>11</issue>):<fpage>2340</fpage>â<lpage>8</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/nar/30.11.2340</pub-id><?supplied-pmid 12034820?><pub-id pub-id-type="pmid">12034820</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0266929.ref065">
      <label>65</label>
      <mixed-citation publication-type="journal"><name><surname>Eriksson</surname><given-names>SE</given-names></name>, <name><surname>Ceder</surname><given-names>S</given-names></name>, <name><surname>Bykov</surname><given-names>VJN</given-names></name>, <name><surname>Wiman</surname><given-names>KG</given-names></name>. <article-title>p53 as a hub in cellular redox regulation and therapeutic target in cancer</article-title>. <source>Journal of Molecular Cell Biology</source>. <year>2019</year>;<volume>11</volume>(<issue>44</issue>):<fpage>330</fpage>â<lpage>41</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/jmcb/mjz005</pub-id><?supplied-pmid 30892598?><pub-id pub-id-type="pmid">30892598</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0266929.ref066">
      <label>66</label>
      <mixed-citation publication-type="journal"><name><surname>Maillet</surname><given-names>A</given-names></name>, <name><surname>Pervaiz</surname><given-names>S</given-names></name>. <article-title>Redox Regulation of p53, Redox Effectors Regulated by p53: A Subtle Balance.</article-title><source>Antioxidants &amp; Redox Signaling</source>. <year>2011</year>;<volume>16</volume>(<issue>11</issue>):<fpage>1285</fpage>â<lpage>94</lpage>.</mixed-citation>
    </ref>
    <ref id="pone.0266929.ref067">
      <label>67</label>
      <mixed-citation publication-type="journal"><name><surname>Hainaut</surname><given-names>P</given-names></name>, <name><surname>Milner</surname><given-names>J</given-names></name>. <article-title>Redox Modulation of p53 Conformation and Sequence-specific DNA Binding &amp;lt;em&amp;gt;in Vitro&amp;lt;/em&amp;gt</article-title>. <source>Cancer Research</source>. <year>1993</year>;<volume>53</volume>(<issue>19</issue>):<fpage>4469</fpage>. <?supplied-pmid 8402615?><pub-id pub-id-type="pmid">8402615</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0266929.ref068">
      <label>68</label>
      <mixed-citation publication-type="journal"><name><surname>Rainwater</surname><given-names>R</given-names></name>, <name><surname>Parks</surname><given-names>D</given-names></name>, <name><surname>Anderson</surname><given-names>ME</given-names></name>, <name><surname>Tegtmeyer</surname><given-names>P</given-names></name>, <name><surname>Mann</surname><given-names>K</given-names></name>. <article-title>Role of cysteine residues in regulation of p53 function</article-title>. <source>Molecular and Cellular Biology</source>. <year>1995</year>;<volume>15</volume>(<issue>77</issue>):<fpage>3892</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1128/MCB.15.7.3892</pub-id><?supplied-pmid 7791795?><pub-id pub-id-type="pmid">7791795</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0266929.ref069">
      <label>69</label>
      <mixed-citation publication-type="journal"><name><surname>Bhargava</surname><given-names>V</given-names></name>, <name><surname>Goldstein</surname><given-names>CD</given-names></name>, <name><surname>Russell</surname><given-names>L</given-names></name>, <name><surname>Xu</surname><given-names>L</given-names></name>, <name><surname>Ahmed</surname><given-names>M</given-names></name>, <name><surname>Li</surname><given-names>W</given-names></name>, <etal>et al</etal>. <article-title>GCNA Preserves Genome Integrity and Fertility Across Species</article-title>. <source>Developmental Cell</source>. <year>2020</year>;<volume>52</volume>(<issue>11</issue>):<fpage>38</fpage>â<lpage>52.e10</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.devcel.2019.11.007</pub-id><?supplied-pmid 31839537?><pub-id pub-id-type="pmid">31839537</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0266929.ref070">
      <label>70</label>
      <mixed-citation publication-type="journal"><name><surname>Carmell</surname><given-names>MA</given-names></name>, <name><surname>Dokshin</surname><given-names>GA</given-names></name>, <name><surname>Skaletsky</surname><given-names>H</given-names></name>, <name><surname>Hu</surname><given-names>Y-C</given-names></name>, <name><surname>van Wolfswinkel</surname><given-names>JC</given-names></name>, <name><surname>Igarashi</surname><given-names>KJ</given-names></name>, <etal>et al</etal>. <article-title>A widely employed germ cell marker is an ancient disordered protein with reproductive functions in diverse eukaryotes</article-title>. <source>eLife</source>. <year>2016</year>;<volume>5</volume>:<fpage>e19993</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.7554/eLife.19993</pub-id><?supplied-pmid 27718356?><pub-id pub-id-type="pmid">27718356</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0266929.ref071">
      <label>71</label>
      <mixed-citation publication-type="journal"><name><surname>Borgermann</surname><given-names>N</given-names></name>, <name><surname>Ackermann</surname><given-names>L</given-names></name>, <name><surname>Schwertman</surname><given-names>P</given-names></name>, <name><surname>Hendriks</surname><given-names>IA</given-names></name>, <name><surname>Thijssen</surname><given-names>K</given-names></name>, <name><surname>Liu</surname><given-names>JC</given-names></name>, <etal>et al</etal>. <article-title>SUMOylation promotes protective responses to DNA-protein crosslinks</article-title>. <source>The EMBO Journal</source>. <year>2019</year>;<volume>38</volume>(<issue>8</issue>):<fpage>e101496</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.15252/embj.2019101496</pub-id><?supplied-pmid 30914427?><pub-id pub-id-type="pmid">30914427</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0266929.ref072">
      <label>72</label>
      <mixed-citation publication-type="journal"><name><surname>DosztÃ¡nyi</surname><given-names>Z</given-names></name>, <name><surname>Csizmok</surname><given-names>V</given-names></name>, <name><surname>Tompa</surname><given-names>P</given-names></name>, <name><surname>Simon</surname><given-names>I</given-names></name>. <article-title>IUPred: web server for the prediction of intrinsically unstructured regions of proteins based on estimated energy content</article-title>. <source>Bioinformatics</source>. <year>2005</year>;<volume>21</volume>(<issue>16</issue>):<fpage>3433</fpage>â<lpage>4</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/bioinformatics/bti541</pub-id><?supplied-pmid 15955779?><pub-id pub-id-type="pmid">15955779</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0266929.ref073">
      <label>73</label>
      <mixed-citation publication-type="journal"><name><surname>Quaglia</surname><given-names>F</given-names></name>, <name><surname>MÃ©szÃ¡ros</surname><given-names>B</given-names></name>, <name><surname>Salladini</surname><given-names>E</given-names></name>, <name><surname>Hatos</surname><given-names>A</given-names></name>, <name><surname>Pancsa</surname><given-names>R</given-names></name>, <name><surname>Chemes</surname><given-names>LB</given-names></name>, <etal>et al</etal>. <article-title>DisProt in 2022: improved quality and accessibility of protein intrinsic disorder annotation</article-title>. <source>Nucleic Acids Research</source>. <year>2021</year>;<volume>50</volume>(<issue>D1</issue>):<fpage>D480</fpage>â<lpage>D7</lpage>.</mixed-citation>
    </ref>
    <ref id="pone.0266929.ref074">
      <label>74</label>
      <mixed-citation publication-type="journal"><name><surname>Basile</surname><given-names>W</given-names></name>, <name><surname>Salvatore</surname><given-names>M</given-names></name>, <name><surname>Bassot</surname><given-names>C</given-names></name>, <name><surname>Elofsson</surname><given-names>A</given-names></name>. <article-title>Why do eukaryotic proteins contain more intrinsically disordered regions?</article-title><source>PLOS Computational Biology</source>. <year>2019</year>;<volume>15</volume>(<issue>77</issue>):<fpage>e1007186</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1371/journal.pcbi.1007186</pub-id><?supplied-pmid 31329574?><pub-id pub-id-type="pmid">31329574</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0266929.ref075">
      <label>75</label>
      <mixed-citation publication-type="journal"><name><surname>Warren</surname><given-names>C</given-names></name>, <name><surname>Shechter</surname><given-names>D</given-names></name>. <article-title>Fly Fishing for Histones: Catch and Release by Histone Chaperone Intrinsically Disordered Regions and Acidic Stretches</article-title>. <source>J Mol Biol</source>. <year>2017</year>;<volume>429</volume>(<issue>16</issue>):<fpage>2401</fpage>â<lpage>26</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.jmb.2017.06.005</pub-id><?supplied-pmid 28610839?><pub-id pub-id-type="pmid">28610839</pub-id></mixed-citation>
    </ref>
    <ref id="pone.0266929.ref076">
      <label>76</label>
      <mixed-citation publication-type="journal"><name><surname>McCarty</surname><given-names>J</given-names></name>, <name><surname>Delaney</surname><given-names>KT</given-names></name>, <name><surname>Danielsen</surname><given-names>SPO</given-names></name>, <name><surname>Fredrickson</surname><given-names>GH</given-names></name>, <name><surname>Shea</surname><given-names>J-E</given-names></name>. <article-title>Complete Phase Diagram for LiquidâLiquid Phase Separation of Intrinsically Disordered Proteins</article-title>. <source>The Journal of Physical Chemistry Letters</source>. <year>2019</year>;<volume>10</volume>(<issue>8</issue>):<fpage>1644</fpage>â<lpage>52</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1021/acs.jpclett.9b00099</pub-id><?supplied-pmid 30873835?><pub-id pub-id-type="pmid">30873835</pub-id></mixed-citation>
    </ref>
  </ref-list>
</back>
<sub-article article-type="aggregated-review-documents" id="pone.0266929.r001" specific-use="decision-letter">
  <front-stub>
    <article-id pub-id-type="doi">10.1371/journal.pone.0266929.r001</article-id>
    <title-group>
      <article-title>Decision Letter 0</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <name>
          <surname>Permyakov</surname>
          <given-names>Eugene A.</given-names>
        </name>
        <role>Academic Editor</role>
      </contrib>
    </contrib-group>
    <permissions>
      <copyright-statement>Â© 2022 Eugene A. Permyakov</copyright-statement>
      <copyright-year>2022</copyright-year>
      <copyright-holder>Eugene A. Permyakov</copyright-holder>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
        <license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
      </license>
    </permissions>
    <related-article ext-link-type="doi" xlink:href="10.1371/journal.pone.0266929" id="rel-obj002" related-article-type="reviewed-article"/>
    <custom-meta-group>
      <custom-meta>
        <meta-name>Submission Version</meta-name>
        <meta-value>0</meta-value>
      </custom-meta>
    </custom-meta-group>
  </front-stub>
  <body>
    <p>
      <named-content content-type="letter-date">7 Jan 2022</named-content>
    </p>
    <p><!-- <div> -->PONE-D-21-38609<!-- </div> --><!-- <div> -->idpr: A package for profiling and analyzing Intrinsically Disordered Proteins in R<!-- </div> --><!-- <div> -->PLOS ONE</p>
    <p>Dear Dr. <!-- <span style="color: rgb(0, 0, 51); font-family: verdana, geneva, arial, helvetica, sans-serif; font-size: 14px; background-color: rgb(244, 244, 244);"> -->Yanowitz<!-- </span> -->,</p>
    <p>Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONEâs publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.</p>
    <p>==============================</p>
    <p>ACADEMIC EDITOR:<!-- </div> --><!-- <div> -->Please try to improve your manuscript according to the reviewers' criticism. It would be good to add some more examples of successful predictions carriied out by your software package.Â </p>
    <p>==============================</p>
    <p>Please submit your revised manuscript by Feb 17 2022 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office atÂ <email>plosone@plos.org</email>. When you're ready to submit your revision, log on to <ext-link xlink:href="https://www.editorialmanager.com/pone/" ext-link-type="uri">https://www.editorialmanager.com/pone/</ext-link> and select the 'Submissions Needing Revision' folder to locate your manuscript file.</p>
    <p>Please include the following items when submitting your revised manuscript:<!-- </div> --><list list-type="bullet"><list-item><p>A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.</p></list-item><list-item><p>A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.</p></list-item><list-item><p>An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.</p></list-item></list></p>
    <p>If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.</p>
    <p>If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: <ext-link xlink:href="https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols" ext-link-type="uri">https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols</ext-link>. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at <ext-link xlink:href="https://plos.org/protocols?utm_medium=editorial-email&amp;utm_source=authorletters&amp;utm_campaign=protocols" ext-link-type="uri">https://plos.org/protocols?utm_medium=editorial-email&amp;utm_source=authorletters&amp;utm_campaign=protocols</ext-link>.</p>
    <p>We look forward to receiving your revised manuscript.</p>
    <p>Kind regards,</p>
    <p>Eugene A. Permyakov, Ph.D., Dr.Sci.</p>
    <p>Academic Editor</p>
    <p>PLOS ONE</p>
    <p>Journal Requirements:</p>
    <p>When submitting your revision, we need you to address these additional requirements.</p>
    <p>1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found atÂ </p>
    <p><ext-link xlink:href="https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf" ext-link-type="uri">https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf</ext-link> andÂ </p>
    <p>
      <ext-link xlink:href="https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf" ext-link-type="uri">https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf</ext-link>
    </p>
    <p>2. To comply with PLOS ONE submissions requirements, please provide the Protocols.io DOI in the Methods section of the manuscript using this format: âThe protocol described in this peer-reviewed article is published on protocols.io, <ext-link xlink:href="https://dx.doi.org/10.17504/protocols.io" ext-link-type="uri">https://dx.doi.org/10.17504/protocols.io</ext-link>[........] and is included for printing as supporting information file 1 with this article.â Please also provide the Protocols.io DOI in the âProtocol DOIâ field of the submission form (via âEdit Submissionâ). For more information, please see our submission guidelines:Â  <ext-link xlink:href="https://journals.plos.org/plosone/s/submission-guidelines#loc-guidelines-for-specific-study-types" ext-link-type="uri">https://journals.plos.org/plosone/s/submission-guidelines#loc-guidelines-for-specific-study-types</ext-link>.</p>
    <p>3. We note you have not provided a Protocol.io PDF version of your protocol. As noted in our submission requirements, please upload a Protocol.io PDF version of your protocol as a Supporting Information file and name the file âS1 fileâ. Please update your Supporting Information Captions if necessary. If you have not yet uploaded your protocol to Protocols.io you are welcome to use the Protocols.io customer service code âPLOS2021.â When using this customer code while submitting to Protocols.io, please make reference to your PLOS ONE submission, including your PLOS ONE manuscript number. With this customer code, Protocols.io editorial staff will import and format your protocol at no charge. For more information, please see our submission guidelines:Â  <ext-link xlink:href="https://journals.plos.org/plosone/s/submission-guidelines#loc-guidelines-for-specific-study-types" ext-link-type="uri">https://journals.plos.org/plosone/s/submission-guidelines#loc-guidelines-for-specific-study-types</ext-link>.</p>
    <p>4. We note that the grant information you provided in the âFunding Informationâ and âFinancial Disclosureâ sections do not match.Â </p>
    <p>When you resubmit, please ensure that you provide the correct grant numbers for the awards you received for your study in the âFunding Informationâ section.</p>
    <p>5.Â We noticed you have some minor occurrence of overlapping text with the following previous publication(s), which needs to be addressed:</p>
    <p>- <ext-link xlink:href="https://rdrr.io/bioc/idpr/f/inst/doc/idpr-vignette.Rmd" ext-link-type="uri">https://rdrr.io/bioc/idpr/f/inst/doc/idpr-vignette.Rmd</ext-link></p>
    <p>In your revision ensure you cite all your sources (including your own works), and quote or rephrase any duplicated text outside the methods section. Further consideration is dependent on these concerns being addressed.</p>
    <p>[Note: HTML markup is below. Please do not edit.]</p>
    <p>Reviewers' comments:</p>
    <p>Reviewer's Responses to Questions</p>
    <p>
      <!-- <font color="black"> -->
      <bold>Comments to the Author</bold>
    </p>
    <p>1. Does the manuscript report a protocol which is of utility to the research community and adds value to the published literature?<!-- </font> --></p>
    <p>Reviewer #1:Â Yes</p>
    <p>Reviewer #2:Â Yes</p>
    <p>**********</p>
    <p><!-- <font color="black"> -->2. Has the protocol been described in sufficient detail?</p>
    <p>Descriptions of methods and reagents contained in the step-by-step protocol should be reported in sufficient detail for another researcher to reproduce all experiments and analyses. The protocol should describe the appropriate controls, sample sizes and replication needed to ensure that the data are robust and reproducible.<!-- </font> --></p>
    <p>Reviewer #1:Â Yes</p>
    <p>Reviewer #2:Â Yes</p>
    <p>**********</p>
    <p><!-- <font color="black"> -->3. Does the protocol describe a validated method?</p>
    <p>The manuscript must demonstrate that the protocol achieves its intended purpose: either by containing appropriate validation data, or referencing at least one original research article in which the protocol was used to generate data.<!-- </font> --></p>
    <p>Reviewer #1:Â No</p>
    <p>Reviewer #2:Â Yes</p>
    <p>**********</p>
    <p><!-- <font color="black"> -->4. If the manuscript contains new data, have the authors made this data fully available?</p>
    <p>The <ext-link xlink:href="http://www.plosone.org/static/policies.action#sharing" ext-link-type="uri">PLOS Data policy</ext-link> requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing dataâe.g. participant privacy or use of data from a third partyâthose must be specified.<!-- </font> --></p>
    <p>Reviewer #1:Â Yes</p>
    <p>Reviewer #2:Â N/A</p>
    <p>**********</p>
    <p>
      <!-- <font color="black"> -->
      <bold>5. Is the article presented in an intelligible fashion and written in standard English?</bold>
    </p>
    <p>PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please highlight any specific errors that need correcting in the box below. <!-- </font> --></p>
    <p>Reviewer #1:Â Yes</p>
    <p>Reviewer #2:Â Yes</p>
    <p>**********</p>
    <p><!-- <font color="black"> -->6. Review Comments to the Author</p>
    <p>Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)<!-- </font> --></p>
    <p>Reviewer #1:Â The manuscript PONE-D-21-38609 presents âidprâ, a software package aimed at the analysis of sequence properties of Intrinsically Disordered Proteins (IDPs) and unfolded protein regions, written by using the programming language R (one of the most common for statistical computing, data mining, and graphical representation). Following the general practice/tradition of reports of software packages, the manuscript illustrates the main features of âidprâ in a succinct way, includes test cases for two well-known IDPs (alpha-synuclein and p53), and refers to the program at the internet address <ext-link xlink:href="https://bioconductor.org/packages/idpr/" ext-link-type="uri">https://bioconductor.org/packages/idpr/</ext-link> for further info; a workflow including instructions for the installation is also provided as Supporting Information.</p>
    <p>This work is interesting and provides a useful tool, because IDPs are currently widely investigated - as explained in the text, they are increasingly recognized as ubiquitously present in all organisms, and heavily involved in many pathologies. The language used is concise and direct, and the presentation is clear enough. Overall, it can be improved as described hereafter.</p>
    <p>Major points:</p>
    <p>- The two test cases presented both involve IDPs that possess large ordered regions. Alpha-synuclein in its functional conformation has 66% of its sequence in helical conformation, and such secondary structure is even folded in a sort of tertiary hairpin structure. Similarly, p53 has a high structural plasticity, but 63% of the sequence adopts a (labile) secondary and tertiary structure. A test case for an entirely unfolded IDP is lacking, and must be added to fully validate the software/protocol presented.</p>
    <p>Any full-unstructured IDP can be chosen to this aim. For instance, NUPR1 (UniProt ID: O60356), a small protein of 82 residues with 0% secondary/tertiary structure (in spite of the wrong prediction of AlphaFold shown on the UniProt page). This protein remains disordered even in molecular complexes, thus is considered a model for a âperfectâ IDP. Peaks in the hydropathy plot of NUPR1 nicely identify hot spots for the binding to molecular partners that include other (folded/unfolded) proteins, peptides, DNA, inorganic polymers, and various drugs, thus it constitutes an interesting and very easy test case. Other proteins, on top of my head, may include p21, prothymosin alpha, and perhaps even some unstructured proteins of SARS-CoV-1/2.</p>
    <p>Minor points:</p>
    <p>- Abstract: please consider mentioning <ext-link xlink:href="https://bioconductor.org/packages/idpr/" ext-link-type="uri">https://bioconductor.org/packages/idpr/</ext-link> already there or, alternatively, as soon as possible.</p>
    <p>- Line 27: âthese proteins have been implicated in several human diseases such as Parkinsonâs Disease, Alzheimerâs Disease, and various cancers (5-7)â. Given the enormous progress of the research in this field, it is disappointing to see that the only papers cited are 10-15 years old. Please consider substituting or complementing them with updated references.</p>
    <p>- Line 46: âthe R package idpr stands for a few things: âIntrinsically Disordered Proteins in Râ and âIDp PRofilesââ. This seems to contradict the Abstract, where a single meaning of the acronym is given. Please correct either the Abstract or, more easily, the text, e.g. âstands for âIntrinsically Disordered Proteins in Râ, although other acronyms such as âIDp PRofilesâ are possibleâ.</p>
    <p>- Line 64: âfasta filesâ. Please call it either FASTA (the correct name for the format) or .fasta (its file extension).</p>
    <p>- Line 67: âtidverse packagesâ. Typo, it is âtidyverseâ.</p>
    <p>- Line 77: âIf a UniPot ID is not included, the IUPred plot is skippedâ. What happens if one wants to investigate a sequence that has not a UniProt ID, e.g. a new mutant of a known sequence? If this is already possible, it should be explained in the text; otherwise, it should be addressed in a future release of âidprâ.</p>
    <p>- Line 81: âMethod described in (16). Mean Scaled Hydropathy calculated with The Kyte and Doolittle measurement of hydropathyâ. It should be âMethods are described...â, and âthe Kyte and Doolittleâ (lowercase âtheâ).</p>
    <p>- Line 98: âextreme net charge and deficiency in hydropathy are characteristics of intrinsic disorder (16)â. It should be specified âintrinsic disorder in proteinsâ (or polypeptides).</p>
    <p>- Line 109: â The resulting figure is similar to ProtScale from ExPASy (38)â. It should be a bit expanded, e.g. âsimilar to the one that can be obtained by using the ProtScale tool from ExPASyâ.</p>
    <p>- Line 116: âOrder promoting residues, meaning those enriched in structured proteins, tend to be aliphatic, hydrophobic, aromatic, or can form tertiary structuresâ. It should be âthose more frequent in structured proteinsâ (structured proteins are enriched of these residues, not the other way around). Also, it should be âprone to form secondary/tertiary structuresâ (any residue âcan formâ such structures, with a few exception such as Prolines in secondary structures; the difference is again in the frequency).</p>
    <p>- Line 117: âDisorder neutral residuesâ. It should be âDisorder-neutral residuesâ, the hyphen is crucial. Please also delete the space in âdisorder- neutral residuesâ, three lines below.</p>
    <p>- Line 139: âResidues with an IUPred2 long scoreâ. The term âlongâ is unclear.</p>
    <p>- Line 162: âThis function can also visualize continuous valuesâ. I cannot understand why it is important to specify this, or imagine an example of an use of such continuous values.</p>
    <p>- Line 181: âaSyn is an IDP, experimentally determined using various methodsâ. Please use âinvestigatedâ, âvalidatedâ, âidentifiedâ, etc., instead of âdeterminedâ.</p>
    <p>- Line 189: âAlthough the protein is deficient in Arg, the local charges of the protein are mostly neutral, apart from...â. I do not see the point of using âAlthoughâ.</p>
    <p>- Line 201: âidentifying biochemical features related to IDPs within a protein of interestâ. Either it was meant âIDRsâ instead of âIDPsâ, or it is not clear.</p>
    <p>- Discussion. This looks more like a Conclusion to me; maybe it can be slightly enlarged.</p>
    <p>- Acknowledgments: It would be nice to state explicitly the names of Dr. M. Buszczak and Dr. M. Brieno-Enriquez.</p>
    <p>Reviewer #2:Â The manuscript describes a relative simple but useful tool for profiling and analysis of intrinsically disordered proteins. The tool is available in R and provides quick analysis and visualization of several relative basic sequence properties of IDPs. These tools should be useful for someone who needs to do quick analysis of these sequence based properties. However, I have some reservation on how useful this tool will be. These properties are quite basic and the targeted users are probably non-experts; yet it require some proficiency in R and scripting to use. It would appear to be much more useful to have a web-based interface for the targeted users. I also recommend the author to build interface to other IDP analysis tools besides IUPred, such as Rohit Pappu's CIDER and others.</p>
    <p>**********</p>
    <p><!-- <font color="black"> -->7. PLOS authors have the option to publish the peer review history of their article (<ext-link xlink:href="https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history" ext-link-type="uri">what does this mean?</ext-link>). If published, this will include your full peer review and any attached files.</p>
    <p>If you choose ânoâ, your identity will remain anonymous but your review may still be made public.</p>
    <p><bold>Do you want your identity to be public for this peer review?</bold> For information about this choice, including consent withdrawal, please see our <ext-link xlink:href="https://www.plos.org/privacy-policy" ext-link-type="uri">Privacy Policy</ext-link>.<!-- </font> --></p>
    <p>Reviewer #1:Â No</p>
    <p>Reviewer #2:Â No</p>
    <p>[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]</p>
    <p>While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool,Â <ext-link xlink:href="https://pacev2.apexcovantage.com/" ext-link-type="uri">https://pacev2.apexcovantage.com/</ext-link>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS atÂ <email>figures@plos.org</email>. Please note that Supporting Information files do not need this step.</p>
  </body>
</sub-article>
<sub-article article-type="author-comment" id="pone.0266929.r002">
  <front-stub>
    <article-id pub-id-type="doi">10.1371/journal.pone.0266929.r002</article-id>
    <title-group>
      <article-title>Author response to Decision Letter 0</article-title>
    </title-group>
    <related-article ext-link-type="doi" xlink:href="10.1371/journal.pone.0266929" id="rel-obj003" related-article-type="editor-report"/>
    <custom-meta-group>
      <custom-meta>
        <meta-name>Submission Version</meta-name>
        <meta-value>1</meta-value>
      </custom-meta>
    </custom-meta-group>
  </front-stub>
  <body>
    <p>
      <named-content content-type="author-response-date">28 Mar 2022</named-content>
    </p>
    <p>Response to Reviewers</p>
    <p>We thank both reviewers for their time and thoughtful comments. They have helped to improve the manuscript and the functionality of the tool itself. Please find below our detailed responses to each point.</p>
    <p>Reviewer #1: The manuscript PONE-D-21-38609 presents âidprâ, a software package aimed at the analysis of sequence properties of Intrinsically Disordered Proteins (IDPs) and unfolded protein regions, written by using the programming language R (one of the most common for statistical computing, data mining, and graphical representation). Following the general practice/tradition of reports of software packages, the manuscript illustrates the main features of âidprâ in a succinct way, includes test cases for two well-known IDPs (alpha-synuclein and p53), and refers to the program at the internet address <ext-link xlink:href="https://bioconductor.org/packages/idpr/" ext-link-type="uri">https://bioconductor.org/packages/idpr/</ext-link> for further info; a workflow including instructions for the installation is also provided as Supporting Information.</p>
    <p>This work is interesting and provides a useful tool, because IDPs are currently widely investigated - as explained in the text, they are increasingly recognized as ubiquitously present in all organisms, and heavily involved in many pathologies. The language used is concise and direct, and the presentation is clear enough. Overall, it can be improved as described hereafter.</p>
    <p>Major points:</p>
    <p>- The two test cases presented both involve IDPs that possess large ordered regions. Alpha-synuclein in its functional conformation has 66% of its sequence in helical conformation, and such secondary structure is even folded in a sort of tertiary hairpin structure. Similarly, p53 has a high structural plasticity, but 63% of the sequence adopts a (labile) secondary and tertiary structure. A test case for an entirely unfolded IDP is lacking, and must be added to fully validate the software/protocol presented.</p>
    <p>Any full-unstructured IDP can be chosen to this aim. For instance, NUPR1 (UniProt ID: O60356), a small protein of 82 residues with 0% secondary/tertiary structure (in spite of the wrong prediction of AlphaFold shown on the UniProt page). This protein remains disordered even in molecular complexes, thus is considered a model for a âperfectâ IDP. Peaks in the hydropathy plot of NUPR1 nicely identify hot spots for the binding to molecular partners that include other (folded/unfolded) proteins, peptides, DNA, inorganic polymers, and various drugs, thus it constitutes an interesting and very easy test case. Other proteins, on top of my head, may include p21, prothymosin alpha, and perhaps even some unstructured proteins of SARS-CoV-1/2.</p>
    <p>We thank the reviewer for their thoughtful comments and their consideration of our manuscript. Your main critique is an excellent point, thank you for this suggestion. We have added a section describing a protein that our lab is currently investigating. As described in the updated manuscript, the Germ Cell Nuclear Acidic protein (GCNA) from Mus musculus is previously reported as, and is predicted to be, entirely disordered. This protein also showcases the relationship of charge and hydropathy previously discussed in the manuscript. </p>
    <p>Minor points:</p>
    <p>- Abstract: please consider mentioning <ext-link xlink:href="https://bioconductor.org/packages/idpr/already" ext-link-type="uri">https://bioconductor.org/packages/idpr/already</ext-link> there or, alternatively, as soon as possible. </p>
    <p>We have added the URL to the abstract.</p>
    <p>- Line 27: âthese proteins have been implicated in several human diseases such as Parkinsonâs Disease, Alzheimerâs Disease, and various cancers (5-7)â. Given the enormous progress of the research in this field, it is disappointing to see that the only papers cited are 10-15 years old. Please consider substituting or complementing them with updated references.</p>
    <p>We have added reference Zbinden, A., PÃ©rez-Berlanga, M., De Rossi, P., and Polymenidou, M. (2020) Phase Separation and Neurodegenerative Diseases: A Disturbance in the Force, Developmental Cell 55, 45-68.</p>
    <p>- Line 46: âthe R package idpr stands for a few things: âIntrinsically Disordered Proteins in Râ and âIDp PRofilesââ. This seems to contradict the Abstract, where a single meaning of the acronym is given. Please correct either the Abstract or, more easily, the text, e.g. âstands for âIntrinsically Disordered Proteins in Râ, although other acronyms such as âIDp PRofilesâ are possibleâ. Addressed by removing multiple acronyms. </p>
    <p>- Line 64: âfasta filesâ. Please call it either FASTA (the correct name for the format) or .fasta (its file extension). Addressed.</p>
    <p>- Line 67: âtidverse packagesâ. Typo, it is âtidyverseâ. </p>
    <p>This is not a typo as some idpr package dependencies are: ggplot2 (&gt;= 3.3.0), magrittr (&gt;= 1.5), dplyr (&gt;= 0.8.5), plyr (&gt;= 1.8.6), which are tidyverse packages <ext-link xlink:href="https://www.tidyverse.org/packages/" ext-link-type="uri">https://www.tidyverse.org/packages/</ext-link> . idpr does not require the user to have the entirety of tidyverse installed. </p>
    <p>- Line 77: âIf a UniPot ID is not included, the IUPred plot is skippedâ. What happens if one wants to investigate a sequence that has not a UniProt ID, e.g. a new mutant of a known sequence? If this is already possible, it should be explained in the text; otherwise, it should be addressed in a future release of âidprâ.</p>
    <p>The IUPred2A web interface allows users to submit any custom sequence, however this cannot be done via the R programming language. The REST API on the IUPred2A server requires a UniProt ID to fetch any prediction, thus we are limited in predictions. Within the idpr package, the iupred(), iupredAnchor(), and iupredRedox() functionsâ help pages and the idpr user manual contains a URL to direct users to the IUPred2A website. Additionally, during revisions we have implemented a second method to predict intrinsically disordered regions, FoldIndex, which does not require a UniProt ID and predicts disorder within R. </p>
    <p>- Line 81: âMethod described in (16). Mean Scaled Hydropathy calculated with The Kyte and Doolittle measurement of hydropathyâ. It should be âMethods are described...â, and âthe Kyte and Doolittleâ (lowercase âtheâ). </p>
    <p> Addressed.</p>
    <p>- Line 98: âextreme net charge and deficiency in hydropathy are characteristics of intrinsic disorder (16)â. It should be specified âintrinsic disorder in proteinsâ (or polypeptides).</p>
    <p>Addressed.</p>
    <p>- Line 109: â The resulting figure is similar to ProtScale from ExPASy (38)â. It should be a bit expanded, e.g. âsimilar to the one that can be obtained by using the ProtScale tool from ExPASyâ.</p>
    <p>Addressed.</p>
    <p>- Line 116: âOrder promoting residues, meaning those enriched in structured proteins, tend to be aliphatic, hydrophobic, aromatic, or can form tertiary structuresâ. It should be âthose more frequent in structured proteinsâ (structured proteins are enriched of these residues, not the other way around). Also, it should be âprone to form secondary/tertiary structuresâ (any residue âcan formâ such structures, with a few exception such as Prolines in secondary structures; the difference is again in the frequency).</p>
    <p>Addressed by adding in âsequences of structured proteinsâ. Addressed by changing âtertiary structuresâ to âdisulfide bondsâ. </p>
    <p>- Line 117: âDisorder neutral residuesâ. It should be âDisorder-neutral residuesâ, the hyphen is crucial. Please also delete the space in âdisorder- neutral residuesâ, three lines below.</p>
    <p>Addressed.</p>
    <p>- Line 139: âResidues with an IUPred2 long scoreâ. The term âlongâ is unclear.</p>
    <p>Addressed by removing âlongâ. </p>
    <p>- Line 162: âThis function can also visualize continuous valuesâ. I cannot understand why it is important to specify this, or imagine an example of an use of such continuous values.</p>
    <p>This is based on the arguments of the ggplot2 package aesthetics that require different color pallets and theme arguments if discrete or continuous variables are visualized. Compare the sequenceMaps in figure 2C which visualizes discrete labels of amino acids to Figure S1B which visualizes continuous values of IUPred2 prediction of intrinsic disorder. </p>
    <p>- Line 181: âaSyn is an IDP, experimentally determined using various methodsâ. Please use âinvestigatedâ, âvalidatedâ, âidentifiedâ, etc., instead of âdeterminedâ. Addressed.</p>
    <p>- Line 189: âAlthough the protein is deficient in Arg, the local charges of the protein are mostly neutral, apart from...â. I do not see the point of using âAlthoughâ. Addressed.</p>
    <p>- Line 201: âidentifying biochemical features related to IDPs within a protein of interestâ. Either it was meant âIDRsâ instead of âIDPsâ, or it is not clear. Addressed.</p>
    <p>- Discussion. This looks more like a Conclusion to me; maybe it can be slightly enlarged.</p>
    <p>We have modified the manuscript headings to reflect this change as we agree this section represents our conclusion. Along with the resulting plots for each of the test cases presented, our results section includes discussion of how previous reports are reflected in these results. Thus, we have changed the âResultsâ section to âResults and Discussionâ and changed the âDiscussionâ section to âConclusionsâ.</p>
    <p>- Acknowledgments: It would be nice to state explicitly the names of Dr. M. Buszczak and Dr. M. Brieno-Enriquez. </p>
    <p>Addressed.</p>
    <p>Reviewer #2: The manuscript describes a relative simple but useful tool for profiling and analysis of intrinsically disordered proteins. The tool is available in R and provides quick analysis and visualization of several relative basic sequence properties of IDPs. These tools should be useful for someone who needs to do quick analysis of these sequence based properties. However, I have some reservation on how useful this tool will be. These properties are quite basic and the targeted users are probably non-experts; yet it require some proficiency in R and scripting to use. It would appear to be much more useful to have a web-based interface for the targeted users. I also recommend the author to build interface to other IDP analysis tools besides IUPred, such as Rohit Pappu's CIDER and others.</p>
    <p>We thank the reviewer for their comments and consideration of our manuscript. We have added another prediction method to the idpr package, FoldIndex. This is now publicly available, documented within the idpr package, and has been updated throughout the manuscript. We thank you for suggesting that we add another prediction method, as this strengthens the utility of the package. </p>
    <p>The goal of the idpr is to simplify these calculations for R users of any skill level. We thank you for raising concern and we have tried to clarify this in the manuscript. Thus, the package has extensive documentation, with a 45-page reference manual and six additional Vignettes (Râs long-form documentation), to guide inexperienced users. To simplify the use for quick analysis, the idprofile serves as a wrapping function for key methods within the package and can return 6 plots with a single line code so long as the user has the sequence .fasta file and the idpr package downloaded: </p>
    <p>```{r}</p>
    <p>idpr::idprofile(sequence = âpath.fastaâ, uniprotAccession = âIDâ) </p>
    <p>```</p>
    <p>However, experienced users will not require this wrapping function and have many options available besides the default settings. All graphing functions in idpr can be set to return results as a data frame containing the amino acid sequence in one column and calculated values in the second column. This enables users to perform downstream analysis, run statistical tests, or create their own custom plots. Thus, idpr is both a calculator for IDP characteristics and a tool to quickly visualize these values for analysis within R. Many prediction tools on the web exist for users who do not have coding experience, what is novel about this package is that it is the first for the R programming language.</p>
    <supplementary-material id="pone.0266929.s003" position="float" content-type="local-data">
      <label>Attachment</label>
      <caption>
        <p>Submitted filename: <named-content content-type="submitted-filename">Response_to_Reviewers.docx</named-content></p>
      </caption>
      <media xlink:href="pone.0266929.s003.docx">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
  </body>
</sub-article>
<sub-article article-type="editor-report" id="pone.0266929.r003" specific-use="decision-letter">
  <front-stub>
    <article-id pub-id-type="doi">10.1371/journal.pone.0266929.r003</article-id>
    <title-group>
      <article-title>Decision Letter 1</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <name>
          <surname>Permyakov</surname>
          <given-names>Eugene A.</given-names>
        </name>
        <role>Academic Editor</role>
      </contrib>
    </contrib-group>
    <permissions>
      <copyright-statement>Â© 2022 Eugene A. Permyakov</copyright-statement>
      <copyright-year>2022</copyright-year>
      <copyright-holder>Eugene A. Permyakov</copyright-holder>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
        <license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
      </license>
    </permissions>
    <related-article ext-link-type="doi" xlink:href="10.1371/journal.pone.0266929" id="rel-obj004" related-article-type="reviewed-article"/>
    <custom-meta-group>
      <custom-meta>
        <meta-name>Submission Version</meta-name>
        <meta-value>1</meta-value>
      </custom-meta>
    </custom-meta-group>
  </front-stub>
  <body>
    <p>
      <named-content content-type="letter-date">30 Mar 2022</named-content>
    </p>
    <p>idpr: A package for profiling and analyzing Intrinsically Disordered Proteins in R</p>
    <p>PONE-D-21-38609R1</p>
    <p>Dear Dr. <!-- <span style="color: rgb(0, 0, 51); font-family: verdana, geneva, arial, helvetica, sans-serif; font-size: 16.8px; background-color: rgb(244, 244, 244);"> -->Yanowitz<!-- </span> -->,</p>
    <p>Weâre pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.</p>
    <p>Within one week, youâll receive an e-mail detailing the required amendments. When these have been addressed, youâll receive a formal acceptance letter and your manuscript will be scheduled for publication.</p>
    <p>An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at <ext-link xlink:href="http://www.editorialmanager.com/pone/" ext-link-type="uri">http://www.editorialmanager.com/pone/</ext-link>, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at <email>authorbilling@plos.org</email>.</p>
    <p>If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If theyâll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <email>onepress@plos.org</email>.</p>
    <p>Kind regards,</p>
    <p>Eugene A. Permyakov, Ph.D., Dr.Sci.</p>
    <p>Academic Editor</p>
    <p>PLOS ONE</p>
    <p>Additional Editor Comments (optional):</p>
    <p>Reviewers' comments:</p>
  </body>
</sub-article>
<sub-article article-type="editor-report" id="pone.0266929.r004" specific-use="acceptance-letter">
  <front-stub>
    <article-id pub-id-type="doi">10.1371/journal.pone.0266929.r004</article-id>
    <title-group>
      <article-title>Acceptance letter</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <name>
          <surname>Permyakov</surname>
          <given-names>Eugene A.</given-names>
        </name>
        <role>Academic Editor</role>
      </contrib>
    </contrib-group>
    <permissions>
      <copyright-statement>Â© 2022 Eugene A. Permyakov</copyright-statement>
      <copyright-year>2022</copyright-year>
      <copyright-holder>Eugene A. Permyakov</copyright-holder>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
        <license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
      </license>
    </permissions>
    <related-article ext-link-type="doi" xlink:href="10.1371/journal.pone.0266929" id="rel-obj005" related-article-type="reviewed-article"/>
  </front-stub>
  <body>
    <p>
      <named-content content-type="letter-date">8 Apr 2022</named-content>
    </p>
    <p>PONE-D-21-38609R1 </p>
    <p>idpr: A package for profiling and analyzing Intrinsically Disordered Proteins in R </p>
    <p>Dear Dr. Yanowitz:</p>
    <p>I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department. </p>
    <p>If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <email>onepress@plos.org</email>.</p>
    <p>If we can help with anything else, please email us at <email>plosone@plos.org</email>. </p>
    <p>Thank you for submitting your work to PLOS ONE and supporting open access. </p>
    <p>Kind regards, </p>
    <p>PLOS ONE Editorial Office Staff</p>
    <p>on behalf of</p>
    <p>Prof. Eugene A. Permyakov </p>
    <p>Academic Editor</p>
    <p>PLOS ONE</p>
  </body>
</sub-article>
